

Financial news for VVUS dated on 2020-06-08: VIVUS Option Alert: Jul 17 \$2 Calls Sweep (11) near the Ask: 1500 @ \$0.221 vs 199 OI; Earnings 8/4 After Close [est] Ref=\$1.13

Financial news for VVUS dated on 2020-06-02: VIVUS Announces Updated Agreement with Icahn Enterprises Holdings L.P.

Financial news for VVUS dated on 2020-05-27: Vivus Shares Ticking Higher After Report That Australian Government Granted Patent For "Methods of preventing progression to type 2 diabetes mellitus"

Financial news for VVUS dated on 2020-05-06: VIVUS Q1 EPS \$(0.490) Beats \$(0.800) Estimate, Sales \$19.631M Beat \$17.700M Estimate

Financial news for VVUS dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for VVUS dated on 2020-05-01: Shares of several healthcare companies are trading lower on market weakness as investor uncertainty grows following quarterly earnings results from multiple companies.

Financial news for VVUS dated on 2020-05-01: Vivus Says on April 29, Entered Into Agreement With Trustee and Holder of About \$170M of Co's Outstanding 4.50% Convertible Senior Notes Due May 1, 2020; Noteholder Agreed to Grant to Co Grace Period With Respect to Payment of Principal Amount of Convertible Notes Payable to Noteholder on May 1

Financial news for VVUS dated on 2020-05-01: VIVUS Reports Deal With IEH Biopharma To Grant 30-Day Grace Period To Restructure Corporate Debt

Financial news for VVUS dated on 2020-04-03: VitalTech Partners With VIVUS Pharmaceuticals To Accelerate Launch Of Telehealth And Remote Patient Monitoring Module

Financial news for VVUS dated on 2020-04-02: 72 Biggest Movers From Yesterday

Financial news for VVUS dated on 2020-04-01: Mid-Afternoon Market Update: Dow Tumbles 800 Points; Chembio Diagnostics Shares Spike Higher

Financial news for VVUS dated on 2020-04-01: Why Vivus Is Trading Lower Today

Financial news for VVUS dated on 2020-04-01: 54 Stocks Moving In Wednesday's Mid-Day Session

Financial news for VVUS dated on 2020-04-01: Mid-Day Market Update: ProPetro Slides After Q4 Results; InflaRx Shares Jump

Financial news for VVUS dated on 2020-04-01: Vivus shares are trading lower after the company priced its ~7.22 Million share common stock offering at \$1.60 per share.

Financial news for VVUS dated on 2020-04-01: Mid-Morning Market Update: Markets Open Lower; UniFirstTops Q2 Estimates

Financial news for VVUS dated on 2020-04-01: VIVUS 13G Filing From Sabby Mgmt. Shows 9.97% Stake

Financial news for VVUS dated on 2020-04-01: VIVUS Prices ~7.22M Share Common Stock Offering At \$1.60/Share

Financial news for VVUS dated on 2020-04-01: 20 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for VVUS dated on 2020-04-01: 31 Stocks Moving in Wednesday's Pre-Market Session

Financial news for VVUS dated on 2020-03-31: Vivus Shares Rally On Accelerated Telemedicine Launch

Financial news for VVUS dated on 2020-03-31: VIVUS Accelerates Launch Of Telemedicine And Remote Monitoring Modules

Financial news for VVUS dated on 2020-03-19: The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latest Stage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

Financial news for VVUS dated on 2020-03-18: Stocks That Hit 52-Week Lows On Wednesday

Financial news for VVUS dated on 2020-03-13: The Daily Biotech Pulse: Roche Obtains

FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

Financial news for VVUS dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for VVUS dated on 2020-03-11: Stocks That Hit 52-Week Lows On Wednesday

Financial news for VVUS dated on 2020-03-10: The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

Financial news for VVUS dated on 2020-03-05: 92 Biggest Movers From Yesterday

Financial news for VVUS dated on 2020-03-04: 60 Stocks Moving In Wednesday's Mid-Day Session

Financial news for VVUS dated on 2020-03-04: Wells Fargo Maintains Equal-Weight on VIVUS, Lowers Price Target to \$1.75

Financial news for VVUS dated on 2020-03-04: The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies

Financial news for VVUS dated on 2020-03-04: 38 Stocks Moving in Wednesday's Pre-Market Session

Financial news for VVUS dated on 2020-03-03: 10 Stocks Moving In Tuesday's After-Hours Session

Financial news for VVUS dated on 2020-03-03: VIVUS shares are trading higher after the company reported better-than-expected Q4 EPS results.

Financial news for VVUS dated on 2020-03-03: VIVUS Q4 EPS \$(0.61) Beats \$(0.68) Estimate, Sales \$17.254M Miss \$19.14M Estimate

Financial news for VVUS dated on 2020-03-03: The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More

Financial news for VVUS dated on 2020-03-02: VIVUS Completes Enrollment in Phase 4 Safety and Efficacy Study of Qsymia in Adolescents

Financial news for VVUS dated on 2020-02-29: The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off

Financial news for VVUS dated on 2020-02-28: Stocks That Hit 52-Week Lows On Friday

Financial news for VVUS dated on 2020-02-28: The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO

Financial news for VVUS dated on 2020-02-27: Stocks That Hit 52-Week Lows On Thursday

Financial news for VVUS dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for VVUS dated on 2020-02-19: 25 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for VVUS dated on 2020-02-19: VIVUS Announces Commercial Launch Of Qsymia In The Republic Of Korea Establishing New Royalty Revenue Stream

Financial news for VVUS dated on 2020-02-06: 90 Biggest Movers From Yesterday

Financial news for VVUS dated on 2020-02-05: Mid-Afternoon Market Update: Greenhill Rises After Q4 Results; PC Connection Shares Slide

Financial news for VVUS dated on 2020-02-05: 68 Stocks Moving In Wednesday's Mid-Day Session

Financial news for VVUS dated on 2020-02-05: Mid-Day Market Update: Crude Oil Up 3.5%; Plantronics Shares Plummet

Financial news for VVUS dated on 2020-02-05: Mid-Morning Market Update: Markets Open Higher; General Motors Posts Mixed Q4 Results

Financial news for VVUS dated on 2020-02-05: VIVUS Receives FDA Approval For Improved Formulation Of PANCREAZE With A 36-Month Shelf Life

Financial news for VVUS dated on 2020-02-03: VIVUS Shares Spike ~13% Over Last Few Mins.; Not Seeing News To Justify Price Action

Financial news for VVUS dated on 2020-01-30: The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance

Financial news for VVUS dated on 2020-01-29: The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut

Financial news for VVUS dated on 2020-01-28: The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics

Financial news for VVUS dated on 2020-01-07: 20 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for VVUS dated on 2020-01-07: VIVUS Highlights Publication Of Data On Qsymia As A Weight Management Tool

Financial news for VVUS dated on 2019-12-31: VIVUS Reports Adoption Of Shareholder Rights Plan

Financial news for VVUS dated on 2019-12-18: 30 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for VVUS dated on 2019-12-18: VIVUS Highlights Publication Of New Data For Qsymia In Adolescents With Obesity

Financial news for VVUS dated on 2019-11-20: VIVUS Announces New Clinical Data Demonstrating Qsymia Effectiveness In Reducing Binge Eating In Bulimia Nervosa Patients

Financial news for VVUS dated on 2019-11-05: VIVUS Q3 EPS \$(1.04) Misses \$(0.74) Estimate, Sales \$17.97M Miss \$20.01M Estimate

Financial news for VVUS dated on 2019-11-05: The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment

Financial news for VVUS dated on 2019-10-07: VIVUS Announces Acceptance of Qsymia Decentralized Marketing Authorization Application in Europe

Financial news for VVUS dated on 2019-10-03: VIVUS Reports Pres Ken Suh, COO Scott Ohrlein To Leave; Replacements Not Mentioned

Financial news for VVUS dated on 2019-10-03: VIVUS Reports Initiation Of Pay Down Of \$48.6M Secured Debt For Total Interest Savings Of \$10.5M

Financial news for VVUS dated on 2019-08-29: 23 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for VVUS dated on 2019-08-26: 60 Biggest Movers From Friday

Financial news for VVUS dated on 2019-08-21: A Look At Benzinga Pro's Most-Searched Tickers For August 21, 2019

Financial news for VVUS dated on 2019-08-21: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wednesday., August 21, 2019

Financial news for VVUS dated on 2019-08-21: 55 Biggest Movers From Yesterday

Financial news for VVUS dated on 2019-08-20: 44 Stocks Moving In Tuesday's Mid-Day Session

Financial news for VVUS dated on 2019-08-20: 22 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for VVUS dated on 2019-08-20: VIVUS Highlights Study Results Showing The Addition Of Co.'s Qsymia To Gastric Sleeve Surgery Significantly Improves Weight Loss Compared with Surgery Alone

Financial news for VVUS dated on 2019-08-06: VIVUS Q2 EPS \$(0.56) Beats \$(0.99) Estimate, Sales \$18.39M Beat \$16.59M Estimate

Financial news for VVUS dated on 2019-06-26: VIVUS And Nordmark Amend Contract Manufacturing Agreement To Supply Current And Future Demand For PANCREAZE

Financial news for VVUS dated on 2019-06-11: VIVUS Launches W-Medicine Platform To Enable Patients With Qsymia Prescriptions To Purchase The Medication Online

Financial news for VVUS dated on 2019-05-30: FDA Reviewed Homepage Of Qsymia Caps For Oral Use Submitted By VIVUS, Says Qsymia Website Makes False, Misleading Claims And/Or Representations About Efficacy Of, Risks Associated With Drug

Financial news for VVUS dated on 2019-05-28: VIVUS Initiates Phase Four Safety and Efficacy Study Of Qsymia In Obese Adolescents

Financial news for VVUS dated on 2019-05-15: VIVUS 8-K Highlights Partnership With HarborPath Direct To Facilitate Access To PANCREAZE For Patients Without Health Insurance

Financial news for VVUS dated on 2019-05-02: VIVUS Shares Spike ~1.5% Over Last Few Mins On Volume As Traders Circulate Word Of New Buy Rating, \$10 Price Target By Zack's Small-Cap Research; BZ NOTE: Zack's Research Doesn't Normally Move Stocks

Financial news for VVUS dated on 2019-04-30: Vivus Q1 EPS \$(0.75) Beats \$(1.17) Estimate, Sales \$16.15M Miss \$16.2M Estimate

Financial news for VVUS dated on 2019-04-17: VIVUS shares are trading higher after traders circulated documents showing the company won a contract award from the Department of Veterans National Acquisition Center.

Financial news for VVUS dated on 2019-04-17: VIVUS Shares Spike ~6% As Traders Circulate FedBizOpps.gov Contract Award Doc From Dept. Of Veterans Affairs National Acquisition Center

Financial news for VVUS dated on 2019-03-14: VIVUS Reports Marketing Approval Of Avanafil In Russian Federation For Treatment Of Erectile Dysfunction

Financial news for VVUS dated on 2019-02-26: Vivus Q4 EPS \$(0.42) Beats \$(0.53) Estimate, Sales \$20.114M Beat \$17M Estimate

Financial news for VVUS dated on 2019-01-15: 56 Biggest Movers From Yesterday

Financial news for VVUS dated on 2019-01-14: 41 Stocks Moving In Monday's Mid-Day Session

Financial news for VVUS dated on 2019-01-14: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for VVUS dated on 2019-01-02: Stocks Which Set New 52-Week Low Today, Wed., Jan. 2, 2019

Financial news for VVUS dated on 2018-12-28: The Daily Biotech Pulse: Opko Settles With SEC, Obalon Inks Financing Deals, Harpoon Files For IPO

Financial news for VVUS dated on 2018-12-27: The Daily Biotech Pulse: Tracon Aces Early-Stage Trials, Boston Scientific To Buy Out Millipede

Financial news for VVUS dated on 2018-12-13: 26 Stocks Moving In Thursday's Pre-Market Session

Financial news for VVUS dated on 2018-12-13: The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen

Financial news for VVUS dated on 2018-12-12: UPDATE: VIVUS, Sanofi Chimie Have Extended Term Of Commercial Supply Deal For Avanafil From Dec. 31, 2018 To Dec. 31, 2023

Financial news for VVUS dated on 2018-12-12: VIVUS 8-K Shows Amendment To Commercial Supply Deal With Sanofi Chimie: Sanofi Chimie Will Manufacture, Supply API For Co.'s Avanafil On Exclusive Basis In All Countries Where Co. Has Right To Sell Drug

Financial news for VVUS dated on 2018-12-10: 48 Biggest Movers From Friday

Financial news for VVUS dated on 2018-12-07: Seeing Sharp Spike In VIVUS Shares; Now Up 26%

Financial news for VVUS dated on 2018-11-28: Stocks Which Set New 52-Week Low Yesterday Tues., Nov. 27, 2018

Financial news for VVUS dated on 2018-11-28: The Daily Biotech Pulse: IntelliPharmaCeutics Generic Antidepressant Gets FDA Nod, GW Pharma Earnings

Financial news for VVUS dated on 2018-11-28: 48 Biggest Movers From Yesterday

Financial news for VVUS dated on 2018-11-27: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for VVUS dated on 2018-11-27: Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 26, 2018

Financial news for VVUS dated on 2018-11-27: The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial

Financial news for VVUS dated on 2018-11-26: Stocks Which Set New 52-Week Low The Prior Trading Session, Fri., Nov. 23, 2018

Financial news for VVUS dated on 2018-11-20: Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 19, 2018

Financial news for VVUS dated on 2018-11-20: The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings

Financial news for VVUS dated on 2018-11-15: The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results

Financial news for VVUS dated on 2018-11-05: 74 Biggest Movers From Friday

Financial news for VVUS dated on 2018-11-01: VIVUS, Inc. Q3 EPS \$(0.87) Down From \$(0.06) YoY, Sales \$18.088M Up From \$15.193M YoY

Financial news for VVUS dated on 2018-09-26: VIVUS Regains Compliance With Nasdaq Listing Requirements

Financial news for VVUS dated on 2018-09-19: 60 Biggest Movers From Yesterday

Financial news for VVUS dated on 2018-09-13: 48 Biggest Movers From Yesterday

Financial news for VVUS dated on 2018-09-12: 38 Stocks Moving In Wednesday's Mid-Day Session

Financial news for VVUS dated on 2018-09-12: VIVUS Halted On Circuit Breaker, Shares Are Up 24.47% At \$6.41/Share

Financial news for VVUS dated on 2018-09-12: 48 Biggest Movers From Yesterday

Financial news for VVUS dated on 2018-09-11: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for VVUS dated on 2018-09-11: VIVUS Inc Shares Halted On Circuit Breaker; Up 11.9%

Financial news for VVUS dated on 2018-09-10: VIVUS Announces 1-For-10 Reverse Stock Split, Effective September 11

Financial news for VVUS dated on 2018-08-07: Vivus Q2 EPS \$(0.12) Misses \$(0.11) Estimate, Sales \$14.96M Miss \$16M Estimate

Financial news for VVUS dated on 2018-07-11: 41 Biggest Movers From Yesterday

Financial news for VVUS dated on 2018-07-10: 32 Stocks Moving In Tuesday's Mid-Day Session

Financial news for VVUS dated on 2018-07-10: Vivus Shares Up 18% Premarket After Co. Announced Positive Preliminary Results From Phase 1 Trial Of VI-0106 For Pulmonary Arterial Hypertension

Financial news for VVUS dated on 2018-07-10: VIVUS Announces Results From Phase 1 Clinical Trial Of VI-0106 In Pulmonary Arterial Hypertension

Financial news for VVUS dated on 2018-06-11: Benzinga Pro's 5 Stocks To Watch Today

Financial news for VVUS dated on 2018-06-11: VIVUS Reports Has Met Closing Conditions For Purchase Of US, Canadian Rights To PANCREAZE Capsules For Treatment Of EPI From J&J's Janssen Pharma For \$135M

Financial news for VVUS dated on 2018-06-08: Roundup Of Biotech Stocks Up On No Positive Catalyst; Dare Bioscience Inc Up 23.2%, ATyr Pharma Up 17.7%, AzurRx BioPharma Up 16.8%, VIVUS Up 8.9%, Innovate Biopharmaceuticals Up 7.7%, IBio Up 6.5%, Evogene Up 6.0%

Financial news for VVUS dated on 2018-06-06: Form 4 Filing Late Tuesday Showed Vivus Director Herm Rosenman Bought 50K Shares at Avg. Price of \$0.77

Financial news for VVUS dated on 2018-05-31: Vivus Director Herm Rosenman Buys 50,000 @ Avg Price: \$0.79

Financial news for VVUS dated on 2018-05-18: Benzinga's Biggest Movers For The Week Of May 14, 2018

Financial news for VVUS dated on 2018-05-18: VIVUS Shares Up 23.2% After Co. Earlier Received Letter From Nasdaq Regarding Continued Listing; Co. Must Have Effected Reverse Stock Split, Evidenced Closing Bid Over \$1/Share On Or Before Oct. 1, '18

Financial news for VVUS dated on 2018-05-18: VIVUS 8-K Shows Co. Received Letter From Nasdaq Informing Co. Hearings Panel Granted Request For Continued Listing Subject To Condition That On Or Before Oct. 1, '18, Co. Must Have Effected Reverse Stock Split, Evidenced Closing Bid Over \$1/Share

Financial news for VVUS dated on 2018-05-17: VIVUS Shares Up 4.1% After Hours As CEO John P Amos Buys 540,000 @ Avg Price: \$0.56

Financial news for VVUS dated on 2018-05-17: Vivus CEO John P Amos Buys 540,000 @ Avg Price: \$0.56

Financial news for VVUS dated on 2018-05-17: UPDATE: FDA Offers Guidelines, Background For Reference Listed Drug Access Inquiries, Related To Claim Of Blocking Generic Rivals

Financial news for VVUS dated on 2018-05-17: FDA Commissioner Scot Gottlieb Highlights List Of Cos. Which Have Potentially Blocked Access To Samples Of Their Branded Products: Pfizer, Biogen, INSYS, VIVUS, Valeant, Corcept Therapeutics

Financial news for VVUS dated on 2018-05-16: Form 4 Filing Late Tuesday Showed Vivus CEO John Amos Bought 540K Shares at \$0.51 to \$0.52

Financial news for VVUS dated on 2018-05-08: Vivus Q1 EPS \$(0.10) Beats \$(0.11) Estimate, Sales \$11.9M Miss \$16M Estimate

Financial news for VVUS dated on 2018-05-01: VIVUS Shares Up 50.7% After Co. Monday Named New CEO and COO, Tuesday Acquired PANCREAZE From Janssen For \$135M

Financial news for VVUS dated on 2018-05-01: VIVUS Restructures Debt and Gains Access to New Capital

Financial news for VVUS dated on 2018-05-01: VIVUS Expands its Commercial Product Portfolio with the Acquisition of PANCREAZE From Janssen For \$135M

Financial news for VVUS dated on 2018-05-01: VIVUS Acquires PANCREAZE from Janssen for \$135M

Financial news for VVUS dated on 2018-04-30: Vivus Names John Amos CEO, Scott Oehrlein COO

Financial news for VVUS dated on 2018-03-13: VIVUS Reports Q4 EPS \$(0.10) vs \$(0.13) Est., Sales \$11.941M vs \$17M Est.

Financial news for VVUS dated on 2018-01-05: Orexigen Struggles As Contrave Commercialization Costs Rise

Financial news for VVUS dated on 2017-12-27: 5 Stocks To Watch For December 27, 2017

Financial news for VVUS dated on 2017-12-26: UPDATE: VIVUS Says Board Is Working With Exec. Search Firm To Help Identify Permanent Replacement At CEO

Financial news for VVUS dated on 2017-12-26: VIVUS Announces CEO Seth Fischer To Step Down; Thomas King Named Interim Replacement

Financial news for VVUS dated on 2017-11-07: Vivus Reports Q3 EPS \$(0.06) vs. \$(0.13) Est., Sales \$15.193M vs. \$16M Est.

Financial news for VVUS dated on 2017-11-02: VIVUS Completes Tacrolimus Pre-IND Meeting With FDA

Financial news for VVUS dated on 2017-09-06: VIVUS Reports Racrolimus Received Orphan Drug Designation In EU For Treatment Of Pulmonary Arterial Hypertension

Financial news for VVUS dated on 2017-09-05: VIVUS and Alvogen Announce Marketing Agreement for Qsymia in the Republic of Korea

Financial news for VVUS dated on 2017-08-30: VIVUS Reports Seeltement With Dr. Reddy's Laboratories On Qsymia Patent Litigation, Dr. Reddy' Will Be Permitted To Sell A Generic Version Starting June 1, 2025

Financial news for VVUS dated on 2017-08-30: EC Public Health Site Shows Orphan Medicinal Products Registry For VIVUS's Tacrolimus For Treatment Of Pulmonary Arterial Hypertension

Financial news for VVUS dated on 2017-08-03: VIVUS Reports Q2 EPS \$(0.13), Inline, Sales \$11.227M vs \$15M Est.

Financial news for VVUS dated on 2017-07-05: VIVUS Reports Settlement Of Qsymia Patent Litigation With Actavis

Financial news for VVUS dated on 2017-05-03: VIVUS Reports Q1 EPS \$(0.01) vs \$(0.14) Est., Sales \$17.62M vs \$13M Est.

Financial news for VVUS dated on 2017-03-27: VIVUS, Inc. Reacquires STENDRA Commercial Rights from Sanofi, Terms Not Disclosed

Financial news for VVUS dated on 2017-03-09: 15 Biggest Mid-Day Gainers For Thursday

Financial news for VVUS dated on 2017-03-09: Mid-Morning Market Update: Markets Edge Higher; Staples Earnings Miss Views

Financial news for VVUS dated on 2017-03-09: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for VVUS dated on 2017-03-08: VIVUS Reports Q4 EPS \$0.54 vs. YoY \$(0.12), Sales \$81.80M vs. YoY \$15.34M

Financial news for VVUS dated on 2017-01-09: VIVUS Enters Settlement Agreement With Hetero USA In Response To Hetero ANDA

Financial news for VVUS dated on 2017-01-09: VIVUS Acquires Development Rights To Selten's Tacrolimus And Ascomycin For Pulmonary Arterial Hypertension

Financial news for VVUS dated on 2016-11-09: VIVUS Reports Q3 EPS \$(0.09) vs. Est. \$(0.19), Rev. \$13.35M vs. Est. \$25.87M

Financial news for VVUS dated on 2016-10-03: VIVUS, Metuchen Pharma Report License Deal for Commercial Rights to STENDRA

Financial news for VVUS dated on 2016-08-29: VIVUS Extends Return Date Of STENDRA Commercial Rights To September 30, 2016

Financial news for VVUS dated on 2016-08-04: VIVUS Reports Q2 EPS \$(0.11) vs \$(0.48) in Same Qtr. Last Year, Sales \$13.776M

Financial news for VVUS dated on 2016-07-27: VIVUS Files Lawsuit Against Hetero for Infringement of Stendra Patents

Financial news for VVUS dated on 2016-07-21: VIVUS Announces Favorable Markman Ruling in Qsymia(R) Patent Litigation

Financial news for VVUS dated on 2016-07-01: Watch These 7 Huge Call Purchases In Friday Trade

Financial news for VVUS dated on 2016-06-30: VIVUS to Extend Return Date of STENDRA Commercial Rights Through August 31, 2016

Financial news for VVUS dated on 2016-06-30: Option Alert: VVUS Aug16 2.0 Calls Sweep: 500 @ ASK \$0.04: 1000 traded vs 150 OI: Earnings 8/4 \$1.13 Ref

Financial news for VVUS dated on 2016-06-21: VIVUS Received Notice From Hetero USA That It Has Filed An ANDA For Generic Versions Of All Strengths Of STENDRA Tablets To The FDA

Financial news for VVUS dated on 2016-06-14: UPDATE: Shares Of Vivus Spiking, Trading \$1.25, Up ~10%

Financial news for VVUS dated on 2016-06-14: UPDATE: Meg Tirrell Tweet Links to NBC News Article 'Which Diet Drug Works Best? It May Depend on You' Published Several Mins Ago

Financial news for VVUS dated on 2016-06-14: Vivus Spikes to High (Now Up 8.6%) Following Tweet from Meg Tirrell Related to Qsymia

Financial news for VVUS dated on 2016-06-14: CNBC's Meg Tirrell Tweets '\$VVUS's Qsymia tops weight loss drug study'

Financial news for VVUS dated on 2016-04-05: North Tide Capital Buys 2,160 Shares of Vivus @ \$1.4017/Share -Form 4

Financial news for VVUS dated on 2016-03-28: North Tide Capital LLC Buys 202,000 Shares of Vivus @\$1.12/Share

Financial news for VVUS dated on 2016-03-09: VIVUS Reports Q4 EPS \$(0.12), Inline, Sales \$15.343M vs \$22.9M Est.

Financial news for VVUS dated on 2016-03-09: Earnings Scheduled For March 9, 2016

Financial news for VVUS dated on 2016-02-29: Vivus And Oreixigen Have Too Many Problems For Investors, RBC's Simeonidis Claims

Financial news for VVUS dated on 2016-02-29: RBC Capital Downgrades Vivus to Sector Perform

Financial news for VVUS dated on 2015-12-31: VIVUS Reports Intent to Repurchase US, Canadian Rights for Stendra, No Terms Disclosed

Financial news for VVUS dated on 2015-12-31: Endo International Notifies Vivus It Will End Its Commercial Supply And License Agreements Related To Avanafil

Financial news for VVUS dated on 2015-12-30: 8-K from Endo Int'l Shows Unit Auxilium Pharma, Endo Ventures, Provided Written Notice to VIVUS Related to Termination of License, Commercialization Deal

Financial news for VVUS dated on 2015-12-01: Hearing Unconfirmed Market Chatter in Vivus Regarding Icahn

Financial news for VVUS dated on 2015-11-04: VIVUS Reports Q3 EPS \$(0.15) vs. Est. \$(0.17), Rev. \$24.936M vs. Est. \$20.24M

Financial news for VVUS dated on 2015-10-08: Morning Market Gainers

Financial news for VVUS dated on 2015-10-08: VVUS +22% Premarket as Icahn Enterprises Announces Expiration of Tender Offer for Outstanding 4.50% Convertible Senior Notes Due 2020

Financial news for VVUS dated on 2015-10-08: Icahn Enterprises L.P. Reports Expiration of Tender Offer for Any and All of the Outstanding 4.50% Convertible Senior Notes Due 2020 of VIVUS, Inc.

Financial news for VVUS dated on 2015-10-05: Vivus 8-K Filing Shows Co Appointed Johann Noor Mohamed As Interim CFO and Chief Accounting Officer

Financial news for VVUS dated on 2015-09-22: VIVUS Board Reports Expression of No Opinion, Remains Neutral Related to Carl Icahn's Bid for Convertible Senior Notes

Financial news for VVUS dated on 2015-09-14: Biotechs Coming Off One Of The Busiest Weeks In Recent Memory

Financial news for VVUS dated on 2015-09-10: Vivus Spikes Higher After-Hours

Financial news for VVUS dated on 2015-09-09: Option Alert: \$VVUS Jan \$2 Call; 1531 Contracts @Ask @\$0.15; Now \$1.38

Financial news for VVUS dated on 2015-09-09: Icahn Enterprises L.P. Reports Tender Offer for Any and All of the Outstanding 4.50% Convertible Senior Notes Due 2020 of VIVUS, Inc.

Financial news for VVUS dated on 2015-09-03: Option Alert: \$VVUS Jan \$2 Call Sweep; 1117 Contracts @Ask @\$0.16, Now \$1.31

Financial news for VVUS dated on 2015-08-18: Mid-Day Market Update: Tuesday's Top Shorted Stocks

Financial news for VVUS dated on 2015-07-31: Stocks Hitting 52-Week Lows

Financial news for VVUS dated on 2015-07-31: Morning Market Losers

Financial news for VVUS dated on 2015-07-30: VIVUS Reports Q2 Loss \$0.48 Vs Est Loss \$0.24, Sales \$23M Vs Est \$18.76M

Financial news for VVUS dated on 2015-07-08: Stocks Hitting 52-Week Lows

Financial news for VVUS dated on 2015-07-06: Benzinga's Top #PreMarket Gainers

Financial news for VVUS dated on 2015-05-05: VIVUS reports Q1 EPS Loss \$0.15 Vs Est Loss \$0.22, Sales \$32.2M Vs Est \$21.76M

Financial news for VVUS dated on 2015-05-05: Earnings Scheduled For May 5, 2015

Financial news for VVUS dated on 2015-04-28: VIVUS Reports New Discount Program for Qsymia Through Sam's Club

Financial news for VVUS dated on 2015-04-21: VIVUS Announces Issuance of Two Additional U.S. Patents for Qsymia

Financial news for VVUS dated on 2015-03-30: VIVUS Offers Operational Update, Including Key Decisions, Plans Related to Qsymia Caps

Financial news for VVUS dated on 2015-03-20: Ferrellgas, Prothena Lead Friday's After-Hours Movers

Financial news for VVUS dated on 2015-03-16: Hearing EMEA in Process to Approve Qsymia in EU

Financial news for VVUS dated on 2015-03-10: 8-K from VIVUS Shows Co. Received Notice from Teva Pharma of Filing with US FDA for ANDA for Generic Versions of All Strengths of Qsymia Capsules CIV

Financial news for VVUS dated on 2015-03-09: Vivus Says on March 4, Co Filed Lawsuit In U.S. District Court for District of NJ vs Actavis, Based on Actavis' Submission Of aNDA Which Infringes Intellectual Property Rights Relating to Qsymia

Financial news for VVUS dated on 2015-02-25: JPM Securities Picks Through Biotech News For Winners

Financial news for VVUS dated on 2015-02-25: Wednesday's #PreMarket Movers: Hewlett-Packard, Dreamworks Animation Trending Lower

Financial news for VVUS dated on 2015-02-24: UPDATE: VIVUS Posts Q4 Loss

Financial news for VVUS dated on 2015-02-24: Vivus Reports Q4 EPS \$(0.25), Rev. \$21.7M

Financial news for VVUS dated on 2015-02-24: Earnings Scheduled For February 24, 2015

Financial news for VVUS dated on 2015-01-29: VIVUS Announces European Approval of SPEDRA Label Amendment

Financial news for VVUS dated on 2015-01-23: Benzinga's Top #PreMarket Gainers

Financial news for VVUS dated on 2015-01-21: Mid-Morning Market Update: Markets Mixed; UnitedHealth Profit Tops Expectations

Financial news for VVUS dated on 2015-01-14: 5 Obesity Stocks Investors Are Watching

Financial news for VVUS dated on 2015-01-13: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4

Financial news for VVUS dated on 2014-12-30: Stocks Hitting 52-Week Lows

Financial news for VVUS dated on 2014-12-19: Orexigen Therapeutics Gains On Diet Pill Nod From European Committee

Financial news for VVUS dated on 2014-12-08: Pharmaceutical Stocks In Play Following Merck/Cubist Deal

Financial news for VVUS dated on 2014-11-26: VIVUS Announces Issuance Of Two Additional U.S. Patents For Qsymia

Financial news for VVUS dated on 2014-11-13: What's Driving Orexigen Therapeutics Higher?

Financial news for VVUS dated on 2014-11-06: Banl Maintains Underperform on VIVUS, Inc., Lowers PT to \$3.00

Financial news for VVUS dated on 2014-11-05: VIVUS, Inc. Reports Q3 EPS of \$(0.15) vs \$(0.25) Est; Revenue of \$33.90M vs \$21.85M Est

Financial news for VVUS dated on 2014-11-05: Earnings Scheduled For November 5, 2014

Financial news for VVUS dated on 2014-10-30: 3 Pharma Companies Fighting Obesity

Financial news for VVUS dated on 2014-10-20: Bank Of America Q3 Small & Mid-Cap Biotech Preview

Financial news for VVUS dated on 2014-09-18: Vivus, Inc. Opens Sharply Higher On ED

Drug Marketing Approval

Financial news for VVUS dated on 2014-09-18: Morning Market Movers

Financial news for VVUS dated on 2014-09-18: UPDATE: VIVUS Shares Rise 20% Premarket on Announcement of FDA Approval Of STENDRA sNDA

Financial news for VVUS dated on 2014-09-18: Benzinga's Top #PreMarket Gainers

Financial news for VVUS dated on 2014-09-18: US Stock Futures Up Ahead Of Jobless Claims, Housing Starts Data

Financial news for VVUS dated on 2014-09-18: VIVUS Auxilium Announce FDA Approval Of STENDRA sNDA

Financial news for VVUS dated on 2014-09-15: Vivus Spikes Lower

Financial news for VVUS dated on 2014-09-11: FDA Panel Says Novo Nordisk's Liraglutide is Safe, Effective for Chronically Obese Patients

Financial news for VVUS dated on 2014-08-25: VIVUS Announces Purchase of Topiramate-Related Patents from J&J's Janssen Pharma, Will Dismiss Suit Against VIVUS

Financial news for VVUS dated on 2014-08-07: VIVUS, Inc. Reports Q2 EPS of \$(0.25) vs \$(0.28) Est; Revenue of \$21.90M vs \$17.90M Est

Financial news for VVUS dated on 2014-06-16: Stocks To Watch For June 16, 2014

Financial news for VVUS dated on 2014-06-12: UPDATE: VIVUS Reports Suit Aaainst Actavis, Cites Infringement of Qsymia Patents

Financial news for VVUS dated on 2014-06-12: VIVUS Reports Suit Aaainst Actavis, Cites Infringement of Qsymia Patents

Financial news for VVUS dated on 2014-06-11: Orexigen Shares Plummet Following FDA Decision; Competition Gets A Bump

Financial news for VVUS dated on 2014-06-09: Is Vivus About To Get Squeezed?

Financial news for VVUS dated on 2014-06-09: Stocks To Watch For June 09, 2014

Financial news for VVUS dated on 2014-06-06: Stocks To Watch For June 06, 2014

Financial news for VVUS dated on 2014-06-04: Option Alert: Vivus Dec \$7 Call; 8,500 Contract Trade at Ask @\$0.35 vs 578 OI; Currently \$5.05

Financial news for VVUS dated on 2014-05-29: Stocks To Watch For May 29, 2014

Financial news for VVUS dated on 2014-05-28: Benzinga's M&A Chatter for Wednesday May 28, 2014

Financial news for VVUS dated on 2014-05-28: Wells Fargo Analyst Issues Note Suggesting a Deal for Vivus Would Not Necessarily Help Address Potential Issues with Qsymia

Financial news for VVUS dated on 2014-05-28: Aspen Buys 9.65% Stake In Vivus, May Acquire Added Holdings

Financial news for VVUS dated on 2014-05-28: Shares of VIVUS Up 13+% Following 13D Filing from Aspen Investment Fund

Financial news for VVUS dated on 2014-05-28: 13D Filing from Aspen Investment Fund on VIVUS Shows 9.65% Stake, Includes Language Will 'Have Talks with Mgmt, Board,' Expects to Make an Offer

Financial news for VVUS dated on 2014-05-09: Form 8-K from VIVUS Shows Actavis Has Filed ANDA for Generic Version of Qsymia

Financial news for VVUS dated on 2014-05-06: Benzinga's Top #PreMarket Gainers

Financial news for VVUS dated on 2014-05-05: VIVUS, Inc. Reports Q1 EPS of \$(0.15) vs \$(0.37) Est; Revenue of \$36.70M vs \$11.40M Est

Financial news for VVUS dated on 2014-05-05: Stocks To Watch For May 05, 2014

Financial news for VVUS dated on 2014-04-22: Option Alert: Vivus Sep \$6 Call; 10,288 Contracts Traded vs 681 OI; Currently \$5.31

Financial news for VVUS dated on 2014-04-08: VIVUS Says Three Directors (Carroll,

Logan, Wilson) Will Not Stand for Reelection

Financial news for VVUS dated on 2014-04-03: Shares of Vivus Fall +10% Following Piper Jaffray's Downgrade

Financial news for VVUS dated on 2014-04-03: Mid-Day Market Update: US Stocks Fall; Google Shares Rise After Stock Split

Financial news for VVUS dated on 2014-04-03: Mid-Morning Market Update: Markets Mostly Flat; Greenbrier Results Beat Estimates

Financial news for VVUS dated on 2014-04-03: Morning Market Losers

Financial news for VVUS dated on 2014-04-03: Benzinga's Top #PreMarket Losers

Financial news for VVUS dated on 2014-04-03: Benzinga's Top Downgrades

Financial news for VVUS dated on 2014-04-03: Piper Jaffray Downgrades VIVUS, Inc. to Underweight, Lowers PT to \$3.00

Financial news for VVUS dated on 2014-03-25: Vivus Announces Review Article Summarizing Cardiovascular Benefit-Risk Profile of Qsymia

Financial news for VVUS dated on 2014-02-25: Market Wrap For February 25: Markets End The Day Relatively Flat

Financial news for VVUS dated on 2014-02-25: Mid-Afternoon Market Update: Markets Turn Red as Tesla Continues to Rip Higher

Financial news for VVUS dated on 2014-02-25: Mid-Day Market Update: US Stocks Mostly Flat; Office Depot Shares Decline On Q4 Results

Financial news for VVUS dated on 2014-02-25: Mid-Morning Market Update: Markets Fall; Home Depot Profit Beats Estimates

Financial news for VVUS dated on 2014-02-25: UPDATE: Vivus Down Nearly 12% After JP Morgan Downgrade on Lackluster Qsymia News

Financial news for VVUS dated on 2014-02-25: Stocks Hitting 52-Week Lows

Financial news for VVUS dated on 2014-02-25: Morning Movers for Feb. 25, 2014: IMUC, MSO, ZU, CARA, VSI, TSLA, XOMA, BCRX Moving Higher, RP, ODP, VVUS, AINV, MGIC, ALSN Lower

Financial news for VVUS dated on 2014-02-25: Benzinga's Top #PreMarket Losers

Financial news for VVUS dated on 2014-02-25: UPDATE: Bank of America Downgrades Vivus as Partnering Prospects Weaken

Financial news for VVUS dated on 2014-02-25: Benzinga's Top Downgrades

Financial news for VVUS dated on 2014-02-25: US Stock Futures Slip Ahead Of Economic Data

Financial news for VVUS dated on 2014-02-25: JP Morgan Downgrades VIVUS, Inc. to Neutral, Lowers PT to \$8.00

Financial news for VVUS dated on 2014-02-25: Bank of America Downgrades VIVUS, Inc. to Underperform, Lowers PO to \$6.00

Financial news for VVUS dated on 2014-02-24: VIVUS, Inc. Reports Q4 EPS of \$(0.17) vs \$(0.40) Est; Revenue of \$44.10M vs \$28.20M Est

Financial news for VVUS dated on 2014-01-21: VIVUS, Auxilium Announce FDA Acceptance of Supplemental Filing Seeking an Update of Prescribing Information for STENDRA

Financial news for VVUS dated on 2014-01-14: Benzinga's Top #PreMarket Gainers

Financial news for VVUS dated on 2014-01-14: VIVUS Announces Will Collaborate with Aetna to Test First Comprehensive Weight Mgmt Program Integrating Weight Loss Medication

Financial news for VVUS dated on 2014-01-02: Vivus Enters Pact With CaremarkPCS Health

Financial news for VVUS dated on 2013-12-27: Form 8-K from VIVUS Shows Co. Says CHMP Feedback on Aqclaim/OB-401 'Generally Positive'

Financial news for VVUS dated on 2013-12-12: UPDATE: Vivus Eligible to Receive Up to

\$61M in Upfront Payments, Regulatory and Sales Milestones; Will Also Receive Escalating Royalties Based Net Sales During Agreement

Financial news for VVUS dated on 2013-12-12: VIVUS Announces License and Commercialization Agreement With Sanofi for Avanafil in Africa, Middle East, Turkey and CIS/Russia

Financial news for VVUS dated on 2013-11-21: Form 8-K from VIVUS Shows Co. Entered Manufacturing & Supply Deal with Sanofi Winthrop, Pact is for Semi-Exclusive Basis in Europe and LatAm

Financial news for VVUS dated on 2013-11-15: Annaly Capital, VIVUS And Others Insiders Have Been Buying

Financial news for VVUS dated on 2013-11-15: Wallachbeth Initiates Coverage on VIVUS, Inc. at Hold, Announces \$11.00 PT

Financial news for VVUS dated on 2013-11-13: VIVUS Awarded Two US Patents for Qsymia; Patent Coverage for Qsymia Extended to 2029

Financial news for VVUS dated on 2013-11-06: Stocks Hitting 52-Week Lows

Financial news for VVUS dated on 2013-11-06: UPDATE: Bank of America Downgrades Vivus on Weaker Partnering Prospects

Financial news for VVUS dated on 2013-11-06: Benzinga's Top Downgrades

Financial news for VVUS dated on 2013-11-06: US Stock Futures Up Ahead Of Time Warner Earnings

Financial news for VVUS dated on 2013-11-06: Bank of America Downgrades VIVUS, Inc. to Neutral, Lowers PO to \$11.00

Financial news for VVUS dated on 2013-11-05: VIVUS, Inc. Reports Q3 EPS of \$(0.48) vs \$(0.38) Est; Revenue of \$6.40M vs \$21.78M Est

Financial news for VVUS dated on 2013-10-31: VIVUS Announces Newly Published Study Finds Qsymia Achieves Greater Weight Loss at Lower Doses Than Either of Its Components as Monotherapy

Financial news for VVUS dated on 2013-10-28: Vivus Spikes Higher

Financial news for VVUS dated on 2013-10-23: Option Alert: Vivus January 11 Call; 7,836 Contracts Traded @\$0.53; Currently \$9.46

Financial news for VVUS dated on 2013-10-23: Vivus Spikes Higher

Financial news for VVUS dated on 2013-10-16: UPDATE: Piper Jaffray Downgrades VIVUS Following Management Meetings

Financial news for VVUS dated on 2013-10-16: Benzinga's Top Pre-Market Losers

Financial news for VVUS dated on 2013-10-16: Piper Jaffray Downgrades VIVUS, Inc. to Neutral

Financial news for VVUS dated on 2013-10-15: Form 8-K from Vivus Discloses Presentation Slides 'Innovative Therapies, Novel Products'

Financial news for VVUS dated on 2013-10-11: Clinton Group Sends Letter to VIVUS CEO, Says Co. Should Do More to Give Info on Strength of 2020 Patents

Financial news for VVUS dated on 2013-10-11: Auxilium Pharmaceuticals Announces License Agreement with Vivus for Marketing Rights to STENDRA In US, Canada

Financial news for VVUS dated on 2013-10-09: Benzinga's Top Pre-Market Gainers

Financial news for VVUS dated on 2013-10-08: VIVUS Says Qsymia Shown to Reduce Progression to Type 2 Diabetes in High-Risk Overweight Patients, Was Well Tolerated by Subgroup Over Two Years

Financial news for VVUS dated on 2013-10-03: Vivus Weighs In As a Leader for Diet Pills, Cowen Upgrades and Raises PT

Financial news for VVUS dated on 2013-10-03: Mid-Day Market Update: Dow Slips Below 15000; CalAmp Jumps On Upbeat Results

Financial news for VVUS dated on 2013-10-03: Benzinga's Volume Movers

Financial news for VVUS dated on 2013-10-03: Mid-Morning Market Update: Markets Open

Lower; Constellation Brands Profit Beats Estimates

Financial news for VVUS dated on 2013-10-03: Benzinga's Top Pre-Market Gainers

Financial news for VVUS dated on 2013-10-03: Benzinga's Top Upgrades

Financial news for VVUS dated on 2013-10-03: Cowen & Company Upgrades VIVUS, Inc. to Outperform, Announces \$19.00 PT

Financial news for VVUS dated on 2013-09-27: VIVUS Says Pres Peter Tam Resigns

Financial news for VVUS dated on 2013-09-24: Stocks Hitting 52-Week Lows

Financial news for VVUS dated on 2013-09-12: Piper Jaffray Cuts Target on VIVUS from \$20 to \$14, Maintains Overweight

Financial news for VVUS dated on 2013-09-09: BMO Considers Recent Sales Data on Arena's Belviq, Maintains Market Perform Rating

Financial news for VVUS dated on 2013-09-07: Duke Energy, VIVUS And Others Insiders Have Been Buying

Financial news for VVUS dated on 2013-09-04: Benzinga's Top Downgrades

Financial news for VVUS dated on 2013-09-04: Lazard Capital Markets Downgrades VIVUS, Inc. to Sell

Financial news for VVUS dated on 2013-09-03: VIVUS Reports Incumbent CEO Has Resigned Amid Health Issues, Co. Names Seth Fischer as CEO

Financial news for VVUS dated on 2013-08-27: Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, VRTX)

Financial news for VVUS dated on 2013-08-06: VIVUS, Inc. Reports Q2 EPS of \$(0.55) vs \$(0.44) Est; Revenue of \$5.53M vs \$12.76M Est

Financial news for VVUS dated on 2013-07-30: Adam F Tweets Vivus Weight-Loss Scripts Surging

Financial news for VVUS dated on 2013-07-26: Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)

Financial news for VVUS dated on 2013-07-23: VIVUS Board Names Michael Astrue as Chairman, Tony Zook as CEO

Financial news for VVUS dated on 2013-07-19: Needham Downgrades VIVUS, Inc. to Hold

Financial news for VVUS dated on 2013-07-19: QVT Financial Reporting New 8.28% Stake In Vivus

Financial news for VVUS dated on 2013-07-19: VIVUS, First Manhattan, Sarissa Capital Announce Settlement Agreement Related to Proxy Contest

Financial news for VVUS dated on 2013-07-18: Bloomberg Reporting Vivus Agrees to Change CEO, Give In to First Manhattan

Financial news for VVUS dated on 2013-07-17: First Manhattan Continues to Seek Fair Settlement

Financial news for VVUS dated on 2013-07-17: A Peek Into The Market Before The Trading Starts

Financial news for VVUS dated on 2013-07-17: First Manhattan Rejects VIVUS Proposal

Financial news for VVUS dated on 2013-07-16: VIVUS Says First Manhattan Made False and Misleading Statements

Financial news for VVUS dated on 2013-07-16: First Manhattan Continues to Seek Settlement Despite Bad Faith Negotiating Tactics from Vivus' Existing Board

Financial news for VVUS dated on 2013-07-15: First Manhattan Issues Statement: Objects to Adjournment of VIVUS Annual Meeting

Financial news for VVUS dated on 2013-07-15: UPDATE: Credit Suisse Downgrades Vivus on Valuation

Financial news for VVUS dated on 2013-07-15: Benzinga's Top Pre-Market Losers

Financial news for VVUS dated on 2013-07-15: Credit Suisse Downgrades VIVUS, Inc. to

Neutral, Maintains PT to \$15.00

Financial news for VVUS dated on 2013-07-15: First Manhattan Responds to Adjournment of Annual Meeting by Vivus Board

Financial news for VVUS dated on 2013-07-14: Vivus Reports First Manhattan's False and Misleading Statements to SEC

Financial news for VVUS dated on 2013-07-14: VIVUS Offers Compromise to First Manhattan

Financial news for VVUS dated on 2013-07-12: Vivus Said to Tell Investors it's Open to Dissident Settlement, Vivus in Proxy Fight with Largest Shareholder First Manhattan

Financial news for VVUS dated on 2013-07-11: Short Interest Rises in Gilead Sciences, Onyx Pharmaceuticals (BIIB, GILD, ONXX)

Financial news for VVUS dated on 2013-07-11: First Manhattan Urges Vivus Shareholders to Elect Nine New Independent Directors

Financial news for VVUS dated on 2013-07-10: VIVUS Issues Statement Ahead of Annual Holder Meeting, Says In Pact with Menarini Group for Spedra

Financial news for VVUS dated on 2013-07-09: VIVUS Board Responds to First Manhattan

Financial news for VVUS dated on 2013-07-08: First Manhattan Reminds Vivus Shareholders That Time is Running out to Save Vivus

Financial news for VVUS dated on 2013-07-05: First Manhattan Says ISS, Egan-Jones Recommend Vivus Shareholders to Vote For Board Nominees, ISS Endorses 3, Egan-Jones Endorses All 9

Financial news for VVUS dated on 2013-07-05: A Peek Into The Market Before The Trading Starts

Financial news for VVUS dated on 2013-07-05: ISS, Glass Lewis Reject FMC's Attempt to Take Control of VIVUS's Board

Financial news for VVUS dated on 2013-07-05: ISS, Egan Jones Recommend Vivus Stockholders Vote for First Manhattan's Board Nominees

Financial news for VVUS dated on 2013-07-02: First Manhattan Announces That Anthony Zook Has Agreed to Serve as Vivus CEO If Its Director Nominees Are Elected

Financial news for VVUS dated on 2013-07-02: VIVUS Mails Letter to Stockholders In Response to First Manhattan Claims

Financial news for VVUS dated on 2013-07-01: VIVUS Announces Availability of Qsymia

Financial news for VVUS dated on 2013-06-28: Investor First Manhattan Issues Update to VIVUS Shareholders

Financial news for VVUS dated on 2013-06-28: VIVUS Clarifies Misstatements by First Manhattan

Financial news for VVUS dated on 2013-06-27: VIVUS Sends Letter to Shareholders In Response to First Manhattan

Financial news for VVUS dated on 2013-06-26: Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, VRTX)

Financial news for VVUS dated on 2013-06-26: VIVUS Announces SPEDRA (avanafil) Approval in Europe

Financial news for VVUS dated on 2013-06-26: Vivus Spikes Higher

Financial news for VVUS dated on 2013-06-25: First Manhattan Outlines Strategic Plan to Fix VIVUS

Financial news for VVUS dated on 2013-06-25: VIVUS Comments on Sam Colin's Questionable Claims

Financial news for VVUS dated on 2013-06-24: Stocks to Watch for June 24, 2013

Financial news for VVUS dated on 2013-06-24: First Manhattan Offers Letter to VIVUS

Financial news for VVUS dated on 2013-06-19: Senators Carper, Murkowski, Representatives Cassidy, Kind Introduce Bill to Help Reduce Obesity

Financial news for VVUS dated on 2013-06-19: Hearing Chatter of Lawmakers Introducing Bill to Require Medicare to Cover Weight-Loss Drugs

Financial news for VVUS dated on 2013-06-19: VIVUS Reports Study Results Demonstrating STENDRA Effective for Sexual Activity within 15 Mins in Men with ED

Financial news for VVUS dated on 2013-06-19: VIVUS Study Shows STENDRA is Effective for Sexual Activity Within 15 Minutes in Men With ED

Financial news for VVUS dated on 2013-06-17: VIVUS Tells Holders to Support Board, Management Team

Financial news for VVUS dated on 2013-06-12: Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB)

Financial news for VVUS dated on 2013-06-07: Article Cites Vivus' Qsymia for Weight Management in People With Type 2 Diabetes

Financial news for VVUS dated on 2013-06-04: First Manhattan Mails Definitive Proxy Statement, Sends Letter to VIVUS Holders, Seeks to Have Nine Nominees Elected to Board

Financial news for VVUS dated on 2013-05-30: Vivus Director E. Mario Has Purchases 15K Shares of the Company's Stock

Financial news for VVUS dated on 2013-05-29: Short Interest in Vertex Rises, in Biogen Idec Falls

Financial news for VVUS dated on 2013-05-23: Stocks to Watch for May 23, 2013

Financial news for VVUS dated on 2013-05-16: Vivus Prices Offering of \$22M in 4.5% Convertible Senior Notes, Says Conversion Rate ~\$14.86/Share

Financial news for VVUS dated on 2013-05-15: Vivus Announces \$200M Convertible Senior Notes Offering

Financial news for VVUS dated on 2013-05-14: Vivus Downgraded Earlier by Lazard on News of Poorly Performing Treatment

Financial news for VVUS dated on 2013-05-14: Stocks to Watch for May 14, 2013

Financial news for VVUS dated on 2013-05-14: Lazard Capital Markets Downgraded VIVUS, Inc. to Neutral

Financial news for VVUS dated on 2013-05-13: VIVUS CEO Issues Letter to Holders, Says In Discussions with Large Pharma Cos.

Financial news for VVUS dated on 2013-05-11: Short Interest in Vertex Rises, in Celgene Falls

Financial news for VVUS dated on 2013-05-09: Stocks to Watch for May 9, 2013

Financial news for VVUS dated on 2013-05-08: VIVUS, Inc. Reports Q1 EPS of \$(0.53) vs \$(0.51) Est; Revenue of \$4.11M vs \$5.22M Est

Financial news for VVUS dated on 2013-05-08: Benzinga Market Primer: Wednesday, May 8

Financial news for VVUS dated on 2013-05-08: Earnings Scheduled For May 8, 2013

Financial news for VVUS dated on 2013-05-07: First Manhattan Releases Case for Full Board Change at Vivus

Financial news for VVUS dated on 2013-05-03: The Week Ahead: Host of Earnings on Tap; Investors Watching Anadarko, Activision, and Whole Foods

Financial news for VVUS dated on 2013-05-01: First Manhattan Responds to VIVUS Board Additions, Says Board Still Needs Overhaul

Financial news for VVUS dated on 2013-04-30: Vivus Shares Volatile as Traders Responding to Piper Jaffray Note Says Qsymia Could Get Medicare, Aetna-Related Updates

Financial news for VVUS dated on 2013-04-30: VIVUS Names Robert Wilson to Board; Says Entered Into Commercial Rebate Pact with Medco April, Patients to Pay Estimated \$50-60 Copay

Financial news for VVUS dated on 2013-04-26: Short Sellers Move into Celgene, Regeneron

Financial news for VVUS dated on 2013-04-19: Vivus Reports 23,812 Qsymia Prescriptions Shipped for Month Ended March 31, 2013 vs 18,417 for Month Ended February 28, 2013 -8-K

Financial news for VVUS dated on 2013-04-18: Stocks to Watch for April 18, 2013

Financial news for VVUS dated on 2013-04-16: VIVUS Announces FDA Approval of Qsymia REMS Modification Allowing Access Through Certified Retail Pharmacies

Financial news for VVUS dated on 2013-04-16: Vivus, Arena Spike Higher

Financial news for VVUS dated on 2013-04-15: Technical Setups for the Week Ahead

Financial news for VVUS dated on 2013-04-11: ETF Showdown: A Pharma Fight

Financial news for VVUS dated on 2013-04-11: Stocks to Watch for April 11, 2013

Financial news for VVUS dated on 2013-04-10: Short Sellers Move Out of Amgen, Celgene, Pharmacyclics

Financial news for VVUS dated on 2013-04-10: First Manhattan Says Expects VIVUS Announcement on QSYMIA

Financial news for VVUS dated on 2013-03-28: Short Sellers Dump Amgen, Focus on Celgene, Gilead Sciences

Financial news for VVUS dated on 2013-03-26: A Peek Into The Market Before The Trading Starts

Financial news for VVUS dated on 2013-03-26: VIVUS Enters into \$110M Non-Equity Financing

Financial news for VVUS dated on 2013-03-14: Option Alert: Vivus January 2014 10 Put; Block Trade: 9,100 Contracts @\$2.10; Currently \$11.23

Financial news for VVUS dated on 2013-03-12: Short Interest Swings in Biotech Stocks (AMGN, CELG, PCYC)

Financial news for VVUS dated on 2013-03-08: VIVUS Confirms Receipt of Notice of Nomination from First Manhattan Co.

Financial news for VVUS dated on 2013-03-08: VIVUS Shares to Open Higher as First Manhattan Showing 8.8% Stake, Says Intends to Nominate Six Directors to Board

Financial news for VVUS dated on 2013-03-06: UPDATE: Piper Jaffray Initiates VIVUS with Overweight on New Category Challenges

Financial news for VVUS dated on 2013-03-05: Piper Jaffray Initiates Coverage on VIVUS, Inc. at Overweight, Announces \$17.00 PT

Financial news for VVUS dated on 2013-03-05: VIVUS Unveils New Offer for Qsymia, to Last for No More Than \$75 Per 30 Days

Financial news for VVUS dated on 2013-02-28: Short Interest Swings in Biotech Stocks (ALXN, AMGN, CELG)

Financial news for VVUS dated on 2013-02-26: Mid-Afternoon Market Update: Markets Go Positive Across the Board, Home Builders Rise

Financial news for VVUS dated on 2013-02-26: Mid-Day Market Update: Cracker Barrel Surges On Upbeat Results, VIVUS Drops

Financial news for VVUS dated on 2013-02-26: UPDATE: Jefferies Cuts PT to \$5, on VIVUS on Qsymia Shortfall, Higher Expenses

Financial news for VVUS dated on 2013-02-26: UPDATE: Bank of America Cuts PO to \$24 on VIVUS on Sluggish Qsymia Launch

Financial news for VVUS dated on 2013-02-26: UPDATE: JP Morgan Cuts PT to \$22 on VIVUS Following Q4 Report

Financial news for VVUS dated on 2013-02-26: Jefferies Maintains Underperform on VIVUS, Inc., Lowers PT to \$5.00

Financial news for VVUS dated on 2013-02-26: Bank of America Maintains Buy on VIVUS, Inc., Lowers PO to \$24.00

Financial news for VVUS dated on 2013-02-26: JP Morgan Maintains Overweight on VIVUS,

Inc., Lowers PT to \$22.00

Financial news for VVUS dated on 2013-02-25: VIVUS, Inc. Reports Q4 EPS of \$(0.56) vs \$(0.44) Est; Revenue of \$1.97M vs \$3.09M Est

Financial news for VVUS dated on 2013-02-25: Benzinga Market Primer: Monday, February 25

Financial news for VVUS dated on 2013-02-25: Earnings Scheduled For February 25, 2013

Financial news for VVUS dated on 2013-02-22: The Week Ahead: Earnings from JC Penney, Groupon, Salesforce

Financial news for VVUS dated on 2013-02-22: UPDATE: Bank of America Reiterates Buy Rating, Lowers PT on Vivus on Failed Qsiva Appeal

Financial news for VVUS dated on 2013-02-21: VIVUS Says EMA Confirmed Oct. MAA Decline, Wants Cardio Outcomes Trial on Qsiva

Financial news for VVUS dated on 2013-02-12: Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)

Financial news for VVUS dated on 2013-02-11: Potential Setups For Next Week

Financial news for VVUS dated on 2013-02-06: Wednesday February 6th Watchlist

Financial news for VVUS dated on 2013-02-06: Leerink Swann Resumed Outperform Rating on VIVUS, Inc.

Financial news for VVUS dated on 2013-02-01: VIVUS Announces Publication of Positive Study on Qsymia

Financial news for VVUS dated on 2013-01-26: Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

Financial news for VVUS dated on 2013-01-24: Pharmas Look to Fatten Up With Obesity Drugs

Financial news for VVUS dated on 2013-01-18: Trading The News

Financial news for VVUS dated on 2013-01-18: UPDATE: First Manhattan Showing 7.2% Stake in VIVUS, Had 4.85% Stake as of Sept. 30th

Financial news for VVUS dated on 2013-01-18: First Manhattan Files 13D on VIVUS

Financial news for VVUS dated on 2013-01-17: Brean Capital Downgrades VIVUS, Inc. to Sell, Announces \$7.00 PT

Financial news for VVUS dated on 2013-01-16: Wednesday January 16th watchlist

Financial news for VVUS dated on 2013-01-14: Vivus Spokesperson Says Volatility in Vivus Shares on Mondays Due to Release of Qsymia Script Data from 3rd-Party Sources

Financial news for VVUS dated on 2013-01-14: Hearing Unconfirmed Market Chatter in Vivus

Financial news for VVUS dated on 2013-01-08: Benzinga's M&A Chatter for Tuesday January 8, 2013

Financial news for VVUS dated on 2013-01-08: UPDATE: Deal Reporter Says Vivus CEO Says Co Could be Acquired, Talks Ongoing

Financial news for VVUS dated on 2013-01-08: Vivus Spikes Higher on Deal Reporter Story Regarding CEO Comments

Financial news for VVUS dated on 2013-01-08: Tuesday January 8th watchlist

Financial news for VVUS dated on 2013-01-07: Mid-Day Market Update: SolarCity Wins Big, SunPower Continues its Fall

Financial news for VVUS dated on 2013-01-07: BofA Earlier Added Vivus Shares to the Firm's 'US 1' List

Financial news for VVUS dated on 2013-01-07: Mid-Morning Market Update: Markets Giving Back Some Gains, Big Banks Catch a Break

Financial news for VVUS dated on 2013-01-07: Benzinga's Top Pre-Market Gainers

Financial news for VVUS dated on 2013-01-07: Vivus Rises 9% Pre-Market; Releases

Slides from JP Morgan Healthcare Conference Presentation in 8K Filing

Financial news for VVUS dated on 2013-01-02: Mid-Afternoon Market Update: Markets Rally Further, VIVUS Remains Down

Financial news for VVUS dated on 2013-01-02: Mid-Day Market Update: Markets Continue Rally, Dole Falls

Financial news for VVUS dated on 2012-12-28: Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)

Financial news for VVUS dated on 2012-12-20: Mid-Morning Market Update: Rite Aid Rallies, New York Stock Exchange Acquired by ICE

Financial news for VVUS dated on 2012-12-20: VIVUS Shares Edge Higher as Express Scripts Adds Qsymia to Benefits Program

Financial news for VVUS dated on 2012-12-18: Tuesday December 18th watchlist

Financial news for VVUS dated on 2012-12-17: Vivus Rallies on Prescription Increase

Financial news for VVUS dated on 2012-12-17: Mid-Afternoon Market Update: Compuware Holds Onto Gains, Clearwire Remains Down

Financial news for VVUS dated on 2012-12-17: Mid-Day Market Update: Compuware Rises; Nam Tai Electronics Drops

Financial news for VVUS dated on 2012-12-17: Mid-Morning Market Update: Caribou Bought Out; Clearwire Plummet

Financial news for VVUS dated on 2012-12-17: VIVUS Shares Open ~8% Higher as Bloomberg Article Highlights 46% Weekly Rise in Prescriptions for the Company's Diet Drug

Financial news for VVUS dated on 2012-12-12: Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

Financial news for VVUS dated on 2012-11-27: Acadia Pharma Rockets Higher on Study Results

Financial news for VVUS dated on 2012-11-27: Vivus Spikes to Highs

Financial news for VVUS dated on 2012-11-26: VIVUS Initiates Qsymia Get Started! Free Trial Offer Program

Financial news for VVUS dated on 2012-11-21: Mid-Day Market Update: Markets Turn Upwards; Scholastic Corporation Takes a Beating

Financial news for VVUS dated on 2012-11-21: Mid-Morning Market Update: Markets Largely Flat; Hostess to Continue With Liquidation

Financial news for VVUS dated on 2012-11-15: QVT Financial Shows 8.3% Stake in VIVUS; QVT Met with VIVUS CEO Urging the Sale of the Co.

Financial news for VVUS dated on 2012-11-15: Mid-Morning Market Update: Markets Start to Recover; DryShips Takes a Hit

Financial news for VVUS dated on 2012-11-15: Lazard Maintains Vivus at Buy, Lowers PT from \$31 to \$27

Financial news for VVUS dated on 2012-11-14: VVUS Starting Payment Assistance Program for Qsymia

Financial news for VVUS dated on 2012-11-12: Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)

Financial news for VVUS dated on 2012-11-12: Vivus Study Finds Significant Improvements in Patients with Obstructive Sleep Apnea Treated With Phentermine And Topiramate Extended-Release Capsules

Financial news for VVUS dated on 2012-11-09: Vivus Spikes to Highs

Financial news for VVUS dated on 2012-11-08: Futures Flat, Euro Falls Ahead of Central Banks

Financial news for VVUS dated on 2012-11-07: Bloomberg Notes Reduction in Analysts' Qsymia Sales Estimates: FY12 from \$20M to \$5M, FY13 from \$200M to \$83M

Financial news for VVUS dated on 2012-11-07: UPDATE: Jefferies & Company Reiterates

Underperform Rating, Lowers PT on VIVUS

Financial news for VVUS dated on 2012-11-07: VIVUS Shares Hit Hard After Earnings

Financial news for VVUS dated on 2012-11-07: Jefferies & Company Maintains Vivus at Underperform, Lowers PT from \$13 to \$6

Financial news for VVUS dated on 2012-11-06: Bank of America Maintains Vivus at Buy, Lowers PT from \$36 to \$30

Financial news for VVUS dated on 2012-11-06: Option Alert: Vivus March 2013 13/20 Call; Block Trade: 8,736 Contracts @\$1.15, Currently \$11.13

Financial news for VVUS dated on 2012-11-06: Mid-Morning Market Update: A Nation Votes, Markets Rise

Financial news for VVUS dated on 2012-11-06: Vivus Reports Q3 EPS \$-0.40 vs \$-0.31 Est; Revenues \$41K vs \$310.00K Est

Financial news for VVUS dated on 2012-11-06: Futures Rise on Election Day

Financial news for VVUS dated on 2012-11-01: Passport Reports 8.55M Share Stake in Vivus, Up From 8.13M

Financial news for VVUS dated on 2012-11-01: John Burbank/Passport Capital Reports Increase in Vivus Stake

Financial news for VVUS dated on 2012-10-25: Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)

Financial news for VVUS dated on 2012-10-18: CHMP Recommends Against Marketing Authorization Application for Vivus' Qsiva

Financial news for VVUS dated on 2012-10-17: VIVUS Submits REMS Amendment To FDA For Qsymia Capsules CIV

Financial news for VVUS dated on 2012-10-15: Short Interest Swings in Biotech Stocks (BIIB, CELG, GILD)

Financial news for VVUS dated on 2012-10-08: Vivus Rises 8%, Crosses \$20

Financial news for VVUS dated on 2012-10-08: Express Scripts Joins Qsymia Certified Home Delivery Pharmacy Network

Financial news for VVUS dated on 2012-10-03: A Peek Into The Market Before The Trading Starts

Financial news for VVUS dated on 2012-10-03: VIVUS Class Action Lawsuit Dismissed

Financial news for VVUS dated on 2012-10-02: Arena Pharmaceuticals and VIVUS Weight Loss Drugs Approved by FDA

Financial news for VVUS dated on 2012-09-24: Jefferies & Company Maintains Vivus at Underperform, Lowers PT from \$16 to \$13

Financial news for VVUS dated on 2012-09-21: Benzinga Mid-Afternoon Market Update

Financial news for VVUS dated on 2012-09-21: Bank of America Maintains Vivus at Buy, Lowers PO from \$40 to \$36

Financial news for VVUS dated on 2012-09-21: Benzinga Mid-Day Market Update

Financial news for VVUS dated on 2012-09-21: Benzinga Mid-Morning Market Update

Financial news for VVUS dated on 2012-09-21: Benzinga's Top Pre-Market Losers

Financial news for VVUS dated on 2012-09-21: EMA Recommends Approval of Nexobrid -Bloomberg

Financial news for VVUS dated on 2012-09-21: VIVUS Says Expects EMA to Reject Qsiva Marketing

Financial news for VVUS dated on 2012-09-18: Benzinga's Top Pre-Market Gainers

Financial news for VVUS dated on 2012-09-18: A Peek Into The Market Before The Trading Starts

Financial news for VVUS dated on 2012-09-18: Vivus Reports Availability of Qsymia

Financial news for VVUS dated on 2012-09-17: Vivus Trading Up Over 3.4% After Announcing That Diet Pill Qsymia Is Now Available for Mail Order Sales

Financial news for VVUS dated on 2012-09-13: Short Sellers Shy Away from Biotech Firms

Financial news for VVUS dated on 2012-08-27: Short Interest in Biotech Firms on the Rise

Financial news for VVUS dated on 2012-08-21: Vivus Spikes Lower, Qsymia Posted in FDA Orange Book

Financial news for VVUS dated on 2012-08-20: Option Alert: Vivus January 2013 30 Call; Block Trade: 6,830 Contracts; Currently \$21.07

Financial news for VVUS dated on 2012-08-17: Social Media Outlook for Friday August 17 (FL, OPLK, VVUS, MAS)

Financial news for VVUS dated on 2012-08-17: Jefferies Downgrades Vivus from Hold to Underperform, Lowers PT from \$31 to \$16

Financial news for VVUS dated on 2012-08-17: Benzinga's Top Downgrades

Financial news for VVUS dated on 2012-08-17: A Peek Into The Market Before The Trading Starts

Financial news for VVUS dated on 2012-08-13: Short Sellers Shy Away from Biotech Firms

Financial news for VVUS dated on 2012-08-07: After-Hours: Vivus Shares Down Following Earnings Update

Financial news for VVUS dated on 2012-08-07: From Earlier: Vivus Upgraded to Buy at Lazard

Financial news for VVUS dated on 2012-07-30: Benzinga Market Primer, Monday July 30

Financial news for VVUS dated on 2012-07-25: Hearing Unconfirmed Vague Chatter in Vivus

Financial news for VVUS dated on 2012-07-20: Social Media Outlook for Friday July 20 (SNDK, BHI, CMG, LCC)

Financial news for VVUS dated on 2012-07-19: Vivus Falls 10% on Citron Research Report

Financial news for VVUS dated on 2012-07-19: Nothing New in the Citron Report on Vivus -Adam F Tweet

Financial news for VVUS dated on 2012-07-19: Vivus Spikes Lower on Citron Research Report

Financial news for VVUS dated on 2012-07-19: Social Media Outlook for Thursday July 19 (SWKS, EBAY, MS, CTRP)

Financial news for VVUS dated on 2012-07-18: UPDATE: Rodman & Renshaw Reiterates Market Outperform Rating, Raises PT on Vivus

Financial news for VVUS dated on 2012-07-18: Wednesday Market Movers

Financial news for VVUS dated on 2012-07-18: Vivus CEO Fully Expects FDA to Approve Third Obesity Drug

Financial news for VVUS dated on 2012-07-18: Vivus CEO Says Qsymia Will Be Introduced In 4Q 2012

Financial news for VVUS dated on 2012-07-18: Benzinga's Top Upgrades

Financial news for VVUS dated on 2012-07-18: JP Morgan Maintains Vivus at Overweight, Raises PT from \$35 to \$38

Financial news for VVUS dated on 2012-07-18: Rodman & Renshaw Maintains Vivus at Market Outperform, Raises PT to \$52

Financial news for VVUS dated on 2012-07-18: Jefferies & Company Upgrades Vivus from Underperform to Hold, Raises PT from \$9 to \$31

Financial news for VVUS dated on 2012-07-17: Arena Pharmaceuticals Spiking Lower on Vivus Qnexa Approval, Orexigen Spiking Higher

Financial news for VVUS dated on 2012-07-17: FDA Approves Vivus Weight-Management Drug Qsymia

Financial news for VVUS dated on 2012-07-17: Vivus Spikes Lower

Financial news for VVUS dated on 2012-07-17: USA Today Prints Retraction on Vivus Qnexa (Qsymia) Approval Story

Financial news for VVUS dated on 2012-07-17: Vivus Spokesperson Says No News of Qnexa FDA Approval Yet

Financial news for VVUS dated on 2012-07-17: Rumors of FDA Approval of Qnexa Due Possibly to USA Today Article Mistakenly Published

Financial news for VVUS dated on 2012-07-17: Hearing Unconfirmed of Vivus' Qnexa Approval

Financial news for VVUS dated on 2012-07-17: Vivus Filed Trademark QSYMIA as Brand Name for Qnexa on June 20, 2012

Financial news for VVUS dated on 2012-07-17: VIVUS Shares Spiking Lower on Possible Bear Raid

Financial news for VVUS dated on 2012-07-16: Option Alert: Heavy Volume in Vivus July 26, 20 and 12 Puts Ahead of Tuesday's Qnexa PDUFA

Financial news for VVUS dated on 2012-07-16: Vivus Spiking Higher Ahead of Tuesday's Qnexa PDUFA Date

Financial news for VVUS dated on 2012-07-13: Jefferies Comments on VIVUS' Qnexa Ahead of FDA Approval

Financial news for VVUS dated on 2012-07-12: Vivus Spikes Lower

Financial news for VVUS dated on 2012-07-09: Vivus Insiders Sell Ahead of FDA Qnexa Decision -Adam F

Financial news for VVUS dated on 2012-07-06: Arena Pharmaceuticals Spikes Higher at Open, Vivus Spikes Lower

Financial news for VVUS dated on 2012-07-05: These Are Four of the Hottest Biotechs in the Market Right Now

Financial news for VVUS dated on 2012-07-02: Top 4 Mid-Cap Stocks In The Biotechnology Industry With The Highest Cash

Financial news for VVUS dated on 2012-06-29: Orexigen Therapeutics Falls 6% on Profit Taking

Financial news for VVUS dated on 2012-06-28: JP Morgan Maintains Vivus at Overweight, Raises PT from \$30 to \$35

Financial news for VVUS dated on 2012-06-27: 4 Breakout Stocks To Watch Thursday

Financial news for VVUS dated on 2012-06-27: FDA Approves Arena's Lorcaserin

Financial news for VVUS dated on 2012-06-27: Arena Approval Boosts Biotech ETFs (ARNA, IBB, XBI)

Financial news for VVUS dated on 2012-06-27: Orexigen Therapeutics Hits 52-Week Highs on Arena Approval

Financial news for VVUS dated on 2012-06-27: Orexigen Therapeutics Crosses \$5/Share on FDA Approval

Financial news for VVUS dated on 2012-06-27: Vivus, Orexigen Spike Higher on Arena Approval

Financial news for VVUS dated on 2012-06-05: UPDATE: VIVUS: CHMP Schedules Oral Hearing On Qnexa Marketing Authorization For September

Financial news for VVUS dated on 2012-06-05: VIVUS Provides Update on Timing of European Decision for Qnexa(R)

Financial news for VVUS dated on 2012-05-31: Vivus' Qnexa Is Not Guaranteed Approval. Remember Provenge?

Financial news for VVUS dated on 2012-05-25: 4 Smaller Alternatives to Big Pharma

Obesity Treatments

Financial news for VVUS dated on 2012-05-22: Option Alert: Vivus July 25/30 Call Spread; 5,325 Contracts; Currently \$23.95

Financial news for VVUS dated on 2012-05-22: Vivus Trading 2% Higher on Heavy Volume; Currently at \$24.09

Financial news for VVUS dated on 2012-05-11: Arena, Vivus, Orexigen are All Takeover Targets -Optionmonster

Financial news for VVUS dated on 2012-05-10: Vivus, Orexigen Spiking Higher After-Hours Following Positive FDA Panel Vote on Arena Diet Drug

Financial news for VVUS dated on 2012-05-10: Vivus Spiking Lower Ahead of FDA Panel Vote On Arena's Lorcaserin

Financial news for VVUS dated on 2012-05-10: FDA in Online Webcast Making Comments About Problems of Obesity

Financial news for VVUS dated on 2012-05-07: Vivus Reports Q1 EPS \$-0.20 vs \$-0.14 Est

Financial news for VVUS dated on 2012-05-07: CDC Says US Obesity Rate Will Increase to 42% of the US

Financial news for VVUS dated on 2012-04-27: UPDATE: Vivus Announces FDA Approval Of STENDRA Tablets For The Treatment Of Erectile Dysfunction

Financial news for VVUS dated on 2012-04-27: Vivus Resumes Trading

Financial news for VVUS dated on 2012-04-27: PREVIEW: Vivus to Resume Trading at 3:40pm

Financial news for VVUS dated on 2012-04-27: Vivus Halted for Pending News

Financial news for VVUS dated on 2012-04-27: Vivus Halted; Pending News

Financial news for VVUS dated on 2012-04-27: Vivus Avanafil Competes with Viagra

Financial news for VVUS dated on 2012-04-27: Vivus Trading 3.2% Higher on Heavy Volume; Currently at \$25.22

Financial news for VVUS dated on 2012-04-27: FDA Approves Vivus' Avanafil

Financial news for VVUS dated on 2012-04-27: Vivus Spokesperson Says PDUFA for Avanafil Sunday April 29, Other Sources Reporting it for Friday April 27

Financial news for VVUS dated on 2012-04-25: UPDATE: Credit Suisse Assumes Outperform, Cuts PT to \$34 on Vivus; Qnexa REMS

Financial news for VVUS dated on 2012-04-18: Vivus Trading 0.9% Higher on Heavy Volume; Currently at \$21.87

Financial news for VVUS dated on 2012-04-10: Bank of America Reported a PDUFA Setback Giving Vivus Hope for REMS Approval

Financial news for VVUS dated on 2012-04-10: Morning Social Media Outlook for Monday April 10 (SFLY, VPHM, TSPT, MOH)

Financial news for VVUS dated on 2012-04-10: Vivus Rises 2.5% on Bank of America Raising PT to \$30

Financial news for VVUS dated on 2012-04-10: UPDATE: Bank of America Raises Vivus' PT

Financial news for VVUS dated on 2012-04-10: Benzinga's Top Pre-Market Losers

Financial news for VVUS dated on 2012-04-10: Bank of America Maintains Vivus at Buy, Raises PO from \$26 to \$30

Financial news for VVUS dated on 2012-04-10: Bank of America Maintains Vivus at Buy, Raises PO from \$26 to \$30

Financial news for VVUS dated on 2012-04-09: Vivus Falls 6% After-Hours on Extension of PDUFA Date for Qnexa

Financial news for VVUS dated on 2012-04-09: UPDATE: VIVUS Qnexa PDUFA Date Extended

Financial news for VVUS dated on 2012-04-09: VIVUS Gets Notification from FDA; PDUFA

Date for Qnexa Extended to July 17

Financial news for VVUS dated on 2012-04-05: Vivus Trading 4.3% Higher on Heavy Volume; Currently at \$23.32

Financial news for VVUS dated on 2012-04-04: Vivus Spiking Higher on Heavy Volume; Currently at \$22.27

Financial news for VVUS dated on 2012-04-03: VVUS Analyst: Wouldn't Be Surprised GSK is Interested in Possible Acquisition, it is Clearly an Acquisition Target

Financial news for VVUS dated on 2012-04-03: Glaxo SmithKline Spokesperson Says Company Does Not Comment on Speculation or Rumor with Regard to Chatter of Vivus Offer

Financial news for VVUS dated on 2012-04-03: Positive Rumors Circulate About Vivus

Financial news for VVUS dated on 2012-03-30: Stocks Close Out Stellar Quarter on High Note; A Look at Top Performers

Financial news for VVUS dated on 2012-03-30: Hearing Summer Street Positive on Vivus

Financial news for VVUS dated on 2012-03-30: Morning Social Media Outlook for Friday March 30 (IMGN, TIBX, XRTX, RIMM)

Financial news for VVUS dated on 2012-03-30: UPDATE: Jefferies Cuts Target to \$9 on VIVUS

Financial news for VVUS dated on 2012-03-30: Vivus Trading 5.2% Higher on Heavy Volume; Currently at \$22.38

Financial news for VVUS dated on 2012-03-30: Hearing Wells Fargo Sees 3-Month PDUFA Delay for Vivus' Qnexa

Financial news for VVUS dated on 2012-03-30: Benzinga's Top Pre-Market Gainers

Financial news for VVUS dated on 2012-03-30: Benzinga's Top Upgrades

Financial news for VVUS dated on 2012-03-30: Financial Breakfast: Morning News Summary for March 30, 2012

Financial news for VVUS dated on 2012-03-30: UPDATE: Brean Murray Carret Upgrades VIVUS to Buy

Financial news for VVUS dated on 2012-03-30: Jefferies & Company Maintains Vivus at Underperform, Lowers PT from \$12 to \$9

Financial news for VVUS dated on 2012-03-30: FDA Spokesperson Says Unlikely That Discussion Over Past Couple of Days Will Impact Any Existing Applications -Adam F. Tweet

Financial news for VVUS dated on 2012-03-30: Brean Murray Carret & Co. Upgrades Vivus from Hold to Buy, Announces PT of \$30

Financial news for VVUS dated on 2012-03-29: US FDA Panel Votes 17-6 Obesity Drugs Without Initial Signal Of Cardiovascular Harm Should Still Be Required To Rule Out Excess Cardiovascular Risk With Clinical Trial Or Meta-Analysis -Reuters

Financial news for VVUS dated on 2012-03-29: UPDATE: FDA Panel Currently Going On

Financial news for VVUS dated on 2012-03-29: Vivus Spiking Higher on Heavy Volume; Currently at \$20.7

Financial news for VVUS dated on 2012-03-29: Option Alert: Vivus April 31 Call; Block Trade, 6,488 Contracts

Financial news for VVUS dated on 2012-03-29: Vivus Spiking Higher on Heavy Volume; Currently at \$20.29

Financial news for VVUS dated on 2012-03-26: Vivus Trading 0.3% Lower on Heavy Volume; Currently at \$21.24

Financial news for VVUS dated on 2012-03-26: Morning Social Media Outlook for Monday March 26 (LGF, A, H, YHOO)

Financial news for VVUS dated on 2012-03-26: Benzinga's Top Pre-Market Gainers

Financial news for VVUS dated on 2012-03-26: A Peek Into The Market Before The Trading Starts

Financial news for VVUS dated on 2012-03-26: Financial Breakfast: Morning News Summary for March 26, 2012

Financial news for VVUS dated on 2012-03-26: VIVUS Announces Acceptance of Avanafil Application in Europe

Financial news for VVUS dated on 2012-03-23: Vivus Spiking Higher

Financial news for VVUS dated on 2012-03-19: Top 4 Setups for Tuesday

Financial news for VVUS dated on 2012-03-19: Vivus Spiking Higher

Financial news for VVUS dated on 2012-03-16: Notable Performers Since the Turn of the Year (AAPL, VVUS, BAC)

Financial news for VVUS dated on 2012-03-15: Vivus Trading 2.7% Higher on Heavy Volume; Currently at \$20.59

Financial news for VVUS dated on 2012-03-13: Vivus Trading 1.2% Lower on Heavy Volume; Currently at \$20

Financial news for VVUS dated on 2012-03-06: JP Morgan Still Positive on Qnexa for VIVUS

Financial news for VVUS dated on 2012-03-06: Hearing JP Morgan Defending Vivus

Financial news for VVUS dated on 2012-03-06: Benzinga's Top Pre-Market Losers

Financial news for VVUS dated on 2012-03-02: Arena Pharma Files for EMA Application, Hopes to Cure Weight Loss

Financial news for VVUS dated on 2012-03-02: Vivus Spiking Higher on Heavy Volume; Currently at \$22.52

Financial news for VVUS dated on 2012-03-01: Vivus Spiking Lower on Heavy Volume; Currently at \$22.29

Financial news for VVUS dated on 2012-03-01: Benzinga's Top Pre-Market Gainers

Financial news for VVUS dated on 2012-03-01: A Peek Into The Market Before The Trading Starts

Financial news for VVUS dated on 2012-03-01: UPDATE: VIVUS Announces Pricing of 9M Share Offering of at \$22.50

Financial news for VVUS dated on 2012-03-01: Vivus Rises 4% on Pricing of Offering of 9M Shares at \$22.50 Wednesday

Financial news for VVUS dated on 2012-02-29: Vivus Rises 4% on Pricing of Offering

Financial news for VVUS dated on 2012-02-29: Vivus Prices 9M Shares at \$22.50

Financial news for VVUS dated on 2012-02-29: Vivus Analyst: The FDA Has Crossed the Rubicon of Balancing Risk and Benefit, Understanding That Obesity is a Pandemic. There Are Not a Lot of Products That Address Such Large Market Opportunities. Vivus Will Not Give This Up Cheaply

Financial news for VVUS dated on 2012-02-29: Vivus Spiking Higher on Chatter of Oversubscription

Financial news for VVUS dated on 2012-02-29: Hearing Chatter Vivus Offering Oversubscribed

Financial news for VVUS dated on 2012-02-29: Vivus Spiking Higher on Heavy Volume; Currently at \$22.8

Financial news for VVUS dated on 2012-02-29: Jefferies & Company Maintains Vivus at Underperform, Raises PT from \$11 to \$12

Financial news for VVUS dated on 2012-02-28: Vivus Q4 EPS \$(0.14) vs \$(0.11) Est

Financial news for VVUS dated on 2012-02-28: Vivus Proposes Offering of 8.5M Shares

Financial news for VVUS dated on 2012-02-28: Vivus CEO Wilson Sells 50K Shares -Form 4

Financial news for VVUS dated on 2012-02-28: Vivus Trading 5% Lower on Heavy Volume; Currently at \$22.6

Financial news for VVUS dated on 2012-02-28: Vivus Spiking Lower

Financial news for VVUS dated on 2012-02-27: Vivus Trending On Social Media

Financial news for VVUS dated on 2012-02-27: Vivus CEO: Looking for Partner Outside of US

Financial news for VVUS dated on 2012-02-27: Vivus CEO: 'Expect Qnexa Approval in April'

Financial news for VVUS dated on 2012-02-27: PREVIEW: Vivus CEO to Appear on CNBC

Financial news for VVUS dated on 2012-02-27: Option Alert: Vivus April 30 Call; Block Trade, 3,844 Contracts

Financial news for VVUS dated on 2012-02-27: Vivus Trading 8% Higher on Heavy Volume; Currently at \$23.89

Financial news for VVUS dated on 2012-02-27: Benzinga's Top Pre-Market Gainers

Financial news for VVUS dated on 2012-02-27: Vivus Spiking Higher Pre-Market

Financial news for VVUS dated on 2012-02-24: Vivus Strength May Be Attributable to Comments From Passport Capital's John Burbank

Financial news for VVUS dated on 2012-02-24: Intra-Day Trading Update: Vivus Showing Significant Strength

Financial news for VVUS dated on 2012-02-24: Vivus Trading 12.2% Higher on Heavy Volume; Currently at \$21.02

Financial news for VVUS dated on 2012-02-24: Vivus Trading 8.9% Higher on Heavy Volume; Currently at \$20.4

Financial news for VVUS dated on 2012-02-24: Morning Social Media Outlook for Friday Feb 24 (DDD, FXEN, CRM, MAR)

Financial news for VVUS dated on 2012-02-24: Vivus Analyst: DCF Model Assumes Fair Value of \$23.35/Share

Financial news for VVUS dated on 2012-02-23: Biopharmaceutical Stock to Watch: VIVUS Massive Move on FDA Approval of Qnexa(r)

Financial news for VVUS dated on 2012-02-23: U.S. Obesity Spells Opportunity for VVUS, OREX and ARNA

Financial news for VVUS dated on 2012-02-23: Vivus Falling to Lows

Financial news for VVUS dated on 2012-02-23: Option Alert: Vivus January 2013 25 Call; Block Trade, 4,900 Contracts

Financial news for VVUS dated on 2012-02-23: Vivus Investors Rejoice as Weight Loss Drug Receives Positive Panel Vote

Financial news for VVUS dated on 2012-02-23: PREVIEW: Vivus CEO Leland F. Wilson to Appear on CNBC Fast Money Halftime Report on Monday February 27

Financial news for VVUS dated on 2012-02-23: Morning Social Media Outlook for Thursday Feb 23 (VVUS, INTU, DELL, HPQ)

Financial news for VVUS dated on 2012-02-23: UPDATE: Bank of England Raises Price Target on Vivus to \$22

Financial news for VVUS dated on 2012-02-23: UPDATE: Brean Murray Carret Upgrades Vivus to Hold

Financial news for VVUS dated on 2012-02-23: UPDATE: Rodman & Renshaw Upgrades Vivus to Outperform

Financial news for VVUS dated on 2012-02-23: Vivus Up 100% After Receiving Positive Panel Vote for Qnexa

Financial news for VVUS dated on 2012-02-23: Rodman & Renshaw Upgrades Vivus from Market Perform to Market Outperform, Maintains PT at \$39

Financial news for VVUS dated on 2012-02-23: Benzinga's Top Pre-Market Gainers

Financial news for VVUS dated on 2012-02-23: Benzinga's Top Upgrades

Financial news for VVUS dated on 2012-02-23: A Peek Into The Market Before The Trading Starts

Financial news for VVUS dated on 2012-02-23: JP Morgan Maintains Vivus at Overweight, Raises PT from \$13 to \$30

Financial news for VVUS dated on 2012-02-23: UPDATE: JP Morgan Raises PT on VIVUS to \$30

Financial news for VVUS dated on 2012-02-23: Bank of America Maintains Vivus at Buy, Raises PO from \$16 to \$22

Financial news for VVUS dated on 2012-02-23: Brean Murray Carret & Co. Upgrades Vivus from Sell to Hold, Removes PT from \$2 to \$

Financial news for VVUS dated on 2012-02-23: Viva Vivus, But Not In ETFs (VVUS, IBB, PJP)

Financial news for VVUS dated on 2012-02-22: UPDATE: Vivus Rises 100% on Positive FDA Panel Vote on Qnexa

Financial news for VVUS dated on 2012-02-22: Arena Pharmaceuticals Rises 19% on Positive FDA Panel Vote on Vivus' Qnexa

Financial news for VVUS dated on 2012-02-22: Vivus Crosses \$20

Financial news for VVUS dated on 2012-02-22: Vivus Rises 88% on Positive FDA Vote

Financial news for VVUS dated on 2012-02-22: Vivus Resumes Trading, Currently Around \$19 on Positive FDA Panel Vote on Qnexa

Financial news for VVUS dated on 2012-02-22: Vivus Resumes Trading

Financial news for VVUS dated on 2012-02-22: PREVIEW: Vivus to Resume Trading at 5:45pm

Financial news for VVUS dated on 2012-02-22: Arena Pharmaceuticals Rises 10% on Positive FDA Panel Vote on Vivus' Qnexa

Financial news for VVUS dated on 2012-02-22: Orexigen Therapeutics and Arena Pharmaceuticals Soar On Positive Qnexa Panel Vote

Financial news for VVUS dated on 2012-02-22: FDA Panel Votes 20-2 In Favor of Approval For Vivus' Qnexa

Financial news for VVUS dated on 2012-02-22: Weight Watchers Falls on FDA Panel Vote on Vivus' Qnexa

Financial news for VVUS dated on 2012-02-22: Weight Watchers Falling a Bit after Vivus Weight-Loss Drug Receives Positive Vote

Financial news for VVUS dated on 2012-02-22: Vivus Receives Positive Vote for Qnexa, 20-2

Financial news for VVUS dated on 2012-02-22: FDA Panel Votes 20 Yes, 2 No in Favor of Vivus' Qnexa

Financial news for VVUS dated on 2012-02-22: Orexigen Therapeutics, Arena Pharmaceuticals Spike Higher as FDA Panels Prepares to Vote on Vivus' Qnexa

Financial news for VVUS dated on 2012-02-22: Vivus: Only 1 Death in Trials, In Placebo Patient

Financial news for VVUS dated on 2012-02-22: Vivus: 70% to 75% of Patients Lost Greater Than 5% of Body Weight

Financial news for VVUS dated on 2012-02-22: Vivus FDA Panel: Qnexa Reduces Blood Pressure, Shows Meaningful Clinical Weight Loss; Still Under Review

Financial news for VVUS dated on 2012-02-22: Vivus: Reducing Obesity and Preventing Diabetes Decreases Birth Defects

Financial news for VVUS dated on 2012-02-22: Vivus: Qnexa Lowers Heart Rate Over One Year in Patients with High Heart Rate

Financial news for VVUS dated on 2012-02-22: Vivus Presentation to FDA Panel Begins

Financial news for VVUS dated on 2012-02-22: Vivus Halted for FDA Panel

Financial news for VVUS dated on 2012-02-21: Benzinga's Volume Losers

Financial news for VVUS dated on 2012-02-21: Vivus Spikes Lower on Negative Street Article

Financial news for VVUS dated on 2012-02-21: A Negative Vote for Vivus Obesity Drug, Says 'FDA Panel Whisperer' -TheStreet

Financial news for VVUS dated on 2012-02-21: Vivus Spiking Lower

Financial news for VVUS dated on 2012-02-17: Vivus Analyst: Membership on FDA Panel is Negatively Biased. Five Members Previously Voted Against an Obesity Drug; Four Have Voted in Favor.

Financial news for VVUS dated on 2012-02-17: Notable Put Options Activity in VIVUS

Financial news for VVUS dated on 2012-02-17: Option Alert: Vivus February 11 Put; Block Trade, 4,802 Contracts

Financial news for VVUS dated on 2012-02-17: Vivus Hoping Weight Loss Drug Will Gain Approval as FDA Releases Briefing Documents

Financial news for VVUS dated on 2012-02-17: FDA Staff Say Qnexa Can Cause Too Much Acid in Body Fluids and Long-Term Effects of This on Overweight and Obese Patients Are Unknown -Reuters

Financial news for VVUS dated on 2012-02-17: FDA Staff Say Qnexa Ingredient Topiramate Is Linked to Cognitive-Related Side Effects Like Confusion and Difficulty with Attention -Reuters

Financial news for VVUS dated on 2012-02-17: Adam Feuerstein: Vivus FDA Briefing Docs Look Like Just the Facts, No Big Conclusions

Financial news for VVUS dated on 2012-02-17: UPDATE: FDA Will Ask Panel Whether A CV Study Will Be Required Prior to Vivus Qnexa Approval

Financial news for VVUS dated on 2012-02-17: Vivus Releases Positive Briefing Documents; Stock Up 7%

Financial news for VVUS dated on 2012-02-16: Hearing Leerink Does Not View Janet Woodcock's Comments as Negative for Vivus

Financial news for VVUS dated on 2012-02-16: Vivus May be Reacting to Comments Made by FDA's Janet Woodcock at Leerink Swann Conference. Trying to Confirm

Financial news for VVUS dated on 2012-02-16: Vivus Analyst: The FDA Will Likely Require a Large Cardiovascular Safety Study of Qnexa Before Approval. Safety Issue of Birth Defects is Secondary to Heart Defect Issue.

Financial news for VVUS dated on 2012-02-16: No FDA Briefing Documents on Vivus Yet

Financial news for VVUS dated on 2012-02-16: Vivus Spiking Lower on Heavy Volume; Currently at \$11.76

Financial news for VVUS dated on 2012-02-16: Vivus Spiking Lower on Heavy Volume; Currently at \$11.58

Financial news for VVUS dated on 2012-02-16: Vivus Trading 7.6% Higher on Heavy Volume; Currently at \$12.91

Financial news for VVUS dated on 2012-02-16: Option Alert: Vivus June 20 Call; Block Trade, 2,700 Contracts

Financial news for VVUS dated on 2012-02-13: Hearing Positive Chatter on Vivus Regarding Upcoming FDA Panel

Financial news for VVUS dated on 2012-02-13: Positive Rumors Circulate About Vivus

Financial news for VVUS dated on 2012-02-13: Option Alert: Vivus June 5 Put; 2,450 Contracts

Financial news for VVUS dated on 2012-02-08: Option Alert: Vivus March 15 Call; Block Trade, 3,388 Contracts

Financial news for VVUS dated on 2012-02-07: Vivus Hits 52-Week High of \$12.86

Financial news for VVUS dated on 2012-01-30: VIVUS: Feb. 22 Date for FDA Advisory Panel of its Obesity Drug, Qnexa

Financial news for VVUS dated on 2012-01-18: Option Alert: Vivus February 12 Call; Block Trade, 3,772 Contracts

Financial news for VVUS dated on 2012-01-17: VIVUS Announces REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function

Financial news for VVUS dated on 2012-01-12: Vivus Hits 52-Week High of \$12.16

Financial news for VVUS dated on 2012-01-11: Vivus Hits 52-Week High of \$12.01

Financial news for VVUS dated on 2012-01-10: Jefferies Maintains Underperform, \$3 PT on VIVUS

Financial news for VVUS dated on 2012-01-10: Rodman & Renshaw Reiterates Perform, \$10-\$11 PT on VVUS

Financial news for VVUS dated on 2012-01-09: Vivus Hits 52-Week High of \$11.67

Financial news for VVUS dated on 2012-01-09: Benzinga's Top Pre-Market Gainers

Financial news for VVUS dated on 2012-01-09: VIVUS Provides Qnexa Regulatory Update; FDA Requests Removal of Contraindication for Women of Childbearing Potential

Financial news for VVUS dated on 2012-01-05: Rodman & Renshaw Initiates VIVUS at Market Perform

Financial news for VVUS dated on 2011-12-23: VIVUS Announces Date of FDA Advisory Committee Review of Qnexa for the Treatment of Obesity

Financial news for VVUS dated on 2011-12-22: End-of-Day Market Summary for December 22, 2011

Financial news for VVUS dated on 2011-12-22: Afternoon Movers; Markets Moved Higher

Financial news for VVUS dated on 2011-12-22: Leerink Swann Downgrades VIVUS to Market Perform

Financial news for VVUS dated on 2011-12-22: Benzinga's Top Pre-Market Losers

Financial news for VVUS dated on 2011-12-22: Benzinga's Top Downgrades

Financial news for VVUS dated on 2011-12-22: Roth Capital Downgrades VIVUS to Neutral

Financial news for VVUS dated on 2011-12-21: VIVUS Reports Topline Findings From FORTRESS

Financial news for VVUS dated on 2011-12-08: UPDATE: Bank of America Raises Price Target on Vivus to \$14

Financial news for VVUS dated on 2011-12-08: Bank of America Raises Po on Vivus to \$14

Financial news for VVUS dated on 2011-12-05: Biotech Stocks On the Move

Financial news for VVUS dated on 2011-12-05: Jefferies Maintains Underperform, \$3 Target on VIVUS

Financial news for VVUS dated on 2011-11-07: Vivus Reports Q3 EPS \$(0.10) vs \$(0.13) Est

Financial news for VVUS dated on 2011-11-04: Credit Suisse Initiating Coverage on Vivus

Financial news for VVUS dated on 2011-11-03: Qnexa Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment

Financial news for VVUS dated on 2011-11-03: VIVUS Announces FDA Accepts New Drug Application Filing for Qnexa

Financial news for VVUS dated on 2011-10-21: Vivus Hopes FDA Approval Will Lead to Fat Profits

Financial news for VVUS dated on 2011-10-17: VIVUS Resubmits Qnexa NDA to the FDA

Financial news for VVUS dated on 2011-10-03: Two-year Treatment With Qnexa Has Benefits Beyond Weight Loss

Financial news for VVUS dated on 2011-09-22: VIVUS: 10% Weight Loss Could Save Medicare \$35 Billion

Financial news for VVUS dated on 2011-09-20: UPDATE: Vivus and Arena Pharmaceuticals Spike Higher on Orexigen Therapeutics News

Financial news for VVUS dated on 2011-09-16: McNicoll, Lewis & Vlak Reiterates Vivus Buy, \$16 PT

Financial news for VVUS dated on 2011-09-15: Notable Call Options Activity in VIVUS

Financial news for VVUS dated on 2011-09-15: Pre-Market Movers; Netflix Down 15%

Financial news for VVUS dated on 2011-09-15: VIVUS Announces Agreement Reached with FDA to Re-Submit QNEXA NDA Prior to Completion of FORTRESS

Financial news for VVUS dated on 2011-09-13: Financial Breakfast: Morning News Summary for September 13, 2011

Financial news for VVUS dated on 2011-09-13: A Peek Into The Market Before The Trading Starts

Financial news for VVUS dated on 2011-09-13: VIVUS Announces Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting

Financial news for VVUS dated on 2011-09-07: Tuesday's NASDAQ Top Gainers

Financial news for VVUS dated on 2011-09-01: VVUS Announces FDA Acceptance of Avanafil NDA

Financial news for VVUS dated on 2011-09-01: VIVUS Announces FDA Acceptance of Avanafil

Financial news for VVUS dated on 2011-09-01: Vivus Spiking Higher on Heavy Volume

Financial news for VVUS dated on 2011-08-23: UPDATE: VIVUS Announces \$45.8 Million Registered Direct Offering of Common Stock at \$6.65/Share

Financial news for VVUS dated on 2011-08-23: UPDATE: Vivus In \$45.8M Registered Direct Offering Of Common Stock; Hearing at \$6.65/Share

Financial news for VVUS dated on 2011-08-23: Vivus In \$45.8M Registered Direct Offering Of Common Stock

Financial news for VVUS dated on 2011-08-05: VIVUS Announces Study Showing Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life

Financial news for VVUS dated on 2011-08-03: McNicoll, Lewis & Vlak Reiterates Vivus Buy, \$16 PT

Financial news for VVUS dated on 2011-08-01: Earnings Scheduled For August 1

Financial news for VVUS dated on 2011-07-28: How to Profit from Exploding Government Healthcare Costs

Financial news for VVUS dated on 2011-07-21: Fifteen Health Care ETFs Trading Near 52-Week Highs

Financial news for VVUS dated on 2011-07-13: Twelve Health Care ETFs Trading Near 52-Week Highs

Financial news for VVUS dated on 2011-07-06: Biotech/Pharma Stocks Investor News Alert

Financial news for VVUS dated on 2011-06-30: A Peek Into The Market Before The Trading Starts

Financial news for VVUS dated on 2011-06-30: VIVUS Submits New Drug Application for Avanafil

Financial news for VVUS dated on 2011-06-22: VIVUS Announces Multiple Presentations Featuring Long-term QNEXA Data at the American Diabetes Association 71st Scientific Sessions

Financial news for VVUS dated on 2011-06-17: A Peek Into The Market Before The Trading Starts

Financial news for VVUS dated on 2011-06-17: VIVUS Announces Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting

Financial news for VVUS dated on 2011-06-03: Benzinga's Top Pre-Market NASDAQ Losers

Financial news for VVUS dated on 2011-05-31: VIVUS Announces Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity

Financial news for VVUS dated on 2011-05-25: MLV Reiterates Buy Rating On Vivus

Financial news for VVUS dated on 2011-05-25: Benzinga's Top Pre-Market NASDAQ Gainers

Financial news for VVUS dated on 2011-05-25: A Peek Into The Market Before The Trading Starts

Financial news for VVUS dated on 2011-05-25: VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients, Met All Primary Endpoints

Financial news for VVUS dated on 2011-05-25: VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients

Financial news for VVUS dated on 2011-05-18: Vivus Trades Higher on Bloomberg Article

Financial news for VVUS dated on 2011-05-17: Arena Pharma Rallies in Sympathy with Vivus Phase 3 Results

Financial news for VVUS dated on 2011-05-17: VIVUS Announces Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting

Financial news for VVUS dated on 2011-05-03: Benzinga's Top Pre-Market NASDAQ Gainers (KLIC, VVUS, ASML, ASMI)

Financial news for VVUS dated on 2011-05-03: Jefferies Comments On VIVUS Safety Analysis

Financial news for VVUS dated on 2011-04-11: Pre-Market Top Percentage Gainers and Losers (GLBC, LVLT, AMMD, ENDP, RAME, VVUS, BIIB, QUIK, MDVN, JACK, EDMC, GS, SINA)

Financial news for VVUS dated on 2011-04-04: Commodities Up on Strength of Emerging Markets 04-04-2011

Financial news for VVUS dated on 2011-04-04: Orexigen And Vivus Surge On Blood Pressure Data (OREX, VVUS)

Financial news for VVUS dated on 2011-04-04: Morning Trade: Top And Bottom Five Percentage Gainers (MSSR, OREX, TFCO, VVUS, CSCD, AMIE, DGW, AFFM, RVSN, IBCPO)

Financial news for VVUS dated on 2011-04-04: Vivus At Highs Of The Session (VVUS)

Financial news for VVUS dated on 2011-04-04: Morning Market Movers (MSSR, ZNVAW, TFCO, VVUS)

Financial news for VVUS dated on 2011-04-04: Benzinga's Top Pre-Market NASDAQ Gainers (VVUS, OREX, CIGX, TEVA)

Financial news for VVUS dated on 2011-03-28: Options Brief: VIVUS, Inc. (VVUS)

Financial news for VVUS dated on 2011-03-04: Running Late 03-04-2011

Financial news for VVUS dated on 2011-03-04: How To Trade Biotech Stocks Better: Trading The NDAs (BIIB, AMGN, VVUS, GENZ, GLD)

Financial news for VVUS dated on 2011-03-04: Puts Active as VIVUS Plunges (VVUS)

Financial news for VVUS dated on 2011-03-04: Vivus Ticks Lower On FDA Caution (VVUS)

Financial news for VVUS dated on 2011-03-01: Fast Money Pops & Drops, March 1st (CCL, BYD, LO, EMN, VVUS)

Financial news for VVUS dated on 2011-02-28: Vivus Reports EPS of \$(0.19) vs. \$(0.22)

Financial news for VVUS dated on 2011-02-02: Setback for Orexigen - Analyst Blog

Financial news for VVUS dated on 2011-02-02: Setback for Orexigen - Analyst Blog

Financial news for VVUS dated on 2011-02-01: What's Hot on TheStreet

Financial news for VVUS dated on 2011-02-01: VIVUS Trading Significantly Lower Today (VVUS)

Financial news for VVUS dated on 2011-02-01: Benzinga's Top Pre-Market NASDAQ Losers (OREX, VVUS, CCME, DEPO)

Financial news for VVUS dated on 2011-02-01: Trading Orexigen Therapeutics Terrible Results (OREX, ARNA, VVUS)

Financial news for VVUS dated on 2011-02-01: Trading Orexigen's FDA Rejection (VVUS, OREX)

Financial news for VVUS dated on 2011-01-21: Benzinga's Top Pre-Market NASDAQ Losers (ACOR, VVUS, SYNA, MNKD)

Financial news for VVUS dated on 2010-12-30: 3 Stocks For New Year's Diets (ARNA, VVUS, OREX)

Financial news for VVUS dated on 2010-12-27: Vivus Seeks EU Nod for Qnexa - Analyst Blog

Financial news for VVUS dated on 2010-12-27: Vivus Seeks EU Nod for Qnexa - Analyst Blog

Financial news for VVUS dated on 2010-12-22: Arena: Long, Hard 'Path' to Obesity Drug Approval

Financial news for VVUS dated on 2010-12-20: Vivus Files Application For Weight Loss Drug (VVUS)

Financial news for VVUS dated on 2010-12-14: Benzinga's Top Pre-Market NASDAQ Losers (OXPS, VVUS, NGPC, LOGI)

Financial news for VVUS dated on 2010-12-14: VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting (VVUS)

Financial news for VVUS dated on 2010-12-13: VIVUS Up Pre-Market

Financial news for VVUS dated on 2010-12-11: Biotech Sector Weekly Rewind

Financial news for VVUS dated on 2010-12-10: Jefferies Comments On New FDA Insight On Obesity Drugs

Financial news for VVUS dated on 2010-12-10: Biotech Stock Mailbag: Orexigen and Vivus

Financial news for VVUS dated on 2010-12-09: ED Drug Could Support Vivus - Analyst Blog

Financial news for VVUS dated on 2010-12-09: ED Drug Could Support Vivus - Analyst Blog

Financial news for VVUS dated on 2010-12-09: Orexigen Therapeutics Dropping After Monster Gain Yesterday

Financial news for VVUS dated on 2010-12-08: FDA Panel Backs OREX's Contrave - Analyst Blog

Financial news for VVUS dated on 2010-12-08: FDA Panel Backs OREX's Contrave - Analyst Blog

Financial news for VVUS dated on 2010-12-08: Biotechnology Stocks Hot Off Of Orexigen Panel Vote

Financial news for VVUS dated on 2010-12-08: Orexigen Therapeutics Off Highs (OREX)

Financial news for VVUS dated on 2010-12-08: Options Brief: VIVUS, Inc. (VVUS)

Financial news for VVUS dated on 2010-12-08: Morning Market Movers (OREX, FCEC, VVUS, ARNA)

Financial news for VVUS dated on 2010-12-08: Vivus Continues Gains Pre-Market on FDA Panel Approval (VVUS)

Financial news for VVUS dated on 2010-12-08: Orexigen Up On FDA Vote

Financial news for VVUS dated on 2010-12-08: Benzinga's Top Pre-Market NASDAQ Gainers (OREX, VVUS, RYAA, AAPL)

Financial news for VVUS dated on 2010-12-07: Men's Wearhouse, Orexigen: After-Hours Trading

Financial news for VVUS dated on 2010-12-07: FDA Panel Approves Orexigen Diet Drug Contrave

Financial news for VVUS dated on 2010-12-07: What Diet Pill Stocks To Trade Alongside Orexigen Therapeutics (OREX, ARNA, VVUS)

Financial news for VVUS dated on 2010-12-07: Vivus Skyrocketing On Vote (VVUS)

Financial news for VVUS dated on 2010-12-07: VIVUS Spiking to New Session Highs (VVUS)

Financial news for VVUS dated on 2010-12-07: Orexigen Therapeutics: FDA Panel Live Blog

Financial news for VVUS dated on 2010-12-06: Benzinga's Top Pre-Market NASDAQ Gainers (VRGY, RDWR, NVMI, VVUS)

Financial news for VVUS dated on 2010-12-03: Orexigen: Predicting Tuesday's FDA Panel

Financial news for VVUS dated on 2010-12-01: Benzinga's After Hours Gainers (PSS, FNSR, VVUS)

Financial news for VVUS dated on 2010-11-30: Orexigen: Contrave FDA Panel Preview

Financial news for VVUS dated on 2010-11-08: VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results: Loss Per Share of \$0.20

Financial news for VVUS dated on 2010-11-07: Mad Money Lightning Round OT: Cramer Thinks That MU Should Be Sold (MU, AMD, CY, VVUS, CAAS, F)

Financial news for VVUS dated on 2010-11-05: Biotech Stock Mailbag: Orexigen

Financial news for VVUS dated on 2010-11-01: Benzinga's Top Pre-Market NASDAQ Losers (VVUS, RYAA, PTNR, VOD)

Financial news for VVUS dated on 2010-11-01: Jefferies Remains Cautious On Vivus Pending Qnexa Approval

Financial news for VVUS dated on 2010-10-29: VIX on the Move Up 10-29-2010

Financial news for VVUS dated on 2010-10-29: Friday's Mid-Day Options Volume Leaders (MSFT, BAC, VVUS, AAPL, AA)

Financial news for VVUS dated on 2010-10-29: Mid-Day Market Movers (IIIIU, FMR, VVUS, MWW)

Financial news for VVUS dated on 2010-10-29: Company News for October 29, 2010 - Corporate Summary

Financial news for VVUS dated on 2010-10-29: Benzinga's Top Pre-Market NASDAQ Gainers (VVUS, PWER, CSTR, MIPS)

Financial news for VVUS dated on 2010-10-29: J.P. Morgan Upgrades Vivus (VVUS)

Financial news for VVUS dated on 2010-10-29: JP Morgan Upgrades VVUS To Overweight

Financial news for VVUS dated on 2010-10-28: Market Listless, Waiting on Elections & Fed

Financial news for VVUS dated on 2010-10-19: Market Watchers See QE Priced Into Market 10-19-2010

Financial news for VVUS dated on 2010-10-18: Vivus Sells MUSE to Meda - Analyst Blog

Financial news for VVUS dated on 2010-10-17: Biotech Stocks to Watch for Monday; (OTCBB: UVFT), (AMEX: PIP), (NASDAQ: VVUS), (NASDAQ: AMGN)

Financial news for VVUS dated on 2010-10-04: Readers Pick Drug Approval Winners & Losers

Financial news for VVUS dated on 2010-09-22: Benzinga's Top Pre-Market NASDAQ Gainers (SEED, VVUS, PWER, RDWR)

Financial news for VVUS dated on 2010-09-22: Benzinga's Top Upgrades (NMR, WSO, VVUS, ENR)

Financial news for VVUS dated on 2010-09-21: Waiting on the Fed 09-21-2010

Financial news for VVUS dated on 2010-09-21: Vivus Soaring On Qnexa Data (VVUS)

Financial news for VVUS dated on 2010-09-21: Benzinga's Top Pre-Market NASDAQ Gainers (TTPA, VVUS, AAWW, BPHX)

Financial news for VVUS dated on 2010-09-17: Benzinga's Top Pre-Market NASDAQ Losers (ARNA, OREX, ACFN, VVUS)

Financial news for VVUS dated on 2010-09-10: More Unconfirmed Chatter On Vivus Takeover (VVUS)

Financial news for VVUS dated on 2010-08-26: VVUS) Unconfirmed rumor that (LLY) will buy the company for \$9.00 Cash

Financial news for VVUS dated on 2010-08-25: Benzinga's After Hours Movers (HBC, PBR, GRMN, JDSU, VVUS, CECO, GES, THC)

Financial news for VVUS dated on 2010-08-05: Vivus Loss Widens - Analyst Blog

Financial news for VVUS dated on 2010-08-03: Vivus's (VVUS) Future Dependent On Qnexa

Financial news for VVUS dated on 2010-08-03: Wells Fargo Lowering Earnings Estimates (CWT, EGN, HK, SM, PFG, DVA, HLS, VVUS, SNH)

Financial news for VVUS dated on 2010-08-02: VIVUS Misses Estimates; Provides Qnexa Update (VVUS)

Financial news for VVUS dated on 2010-07-16: Bears Grab Control on Heavier Volume 07-16-2010

Financial news for VVUS dated on 2010-07-16: Vivus Tumbles 70% on FDA Disapproval; Piper Jaffray Urges You to Buy Arena (ARNA, VVUS)

Financial news for VVUS dated on 2010-07-16: Vivus (VVUS) Drops More Than 56% As FDA Rejects Qnexa

Financial news for VVUS dated on 2010-07-16: Benzinga's Top Pre-Market NASDAQ Losers (VVUS, OREX, PLCM, MAT)

Financial news for VVUS dated on 2010-07-16: Vivus (VVUS) Cut To Neutral By JP Morgan

Financial news for VVUS dated on 2010-07-15: Benzinga's After Hours Decliners (GOOG, DF, VVUS)

Financial news for VVUS dated on 2010-07-15: FDA Panel Rejects Vivus Drug (VVUS)

Financial news for VVUS dated on 2010-07-14: Unemployment Impacting Retail Sales 07-14-2010

Financial news for VVUS dated on 2010-07-14: Benzinga's Top Upgrades (ENR, CRM, VVUS, AKS)

Financial news for VVUS dated on 2010-07-13: SPX Breaks Key 1085 Resistance 07-13-2010

Financial news for VVUS dated on 2010-07-13: Benzinga's Volume Movers (ADCT, VVUS, EZCH, ACTG)

Financial news for VVUS dated on 2010-07-13: VVUS Soars Following FDA's Statement On Qnexa

Financial news for VVUS dated on 2010-07-13: Benzinga's Top Pre-Market Gainers (VVUS, OREX, ARNA, CENX)

Financial news for VVUS dated on 2010-07-09: Slow Trading - But Stay On Your Toes 07-09-2010

Financial news for VVUS dated on 2010-07-08: Jefferies Concern About Neuropsychiatric Profile Of Qnexa: VVUS

Financial news for VVUS dated on 2010-07-07: Short Vol Position Closed on Vivus (VVUS)

Financial news for VVUS dated on 2010-06-28: Arena And Vivus Receive 'Hold' Rating from Jefferies (ARNA, VVUS)

Financial news for VVUS dated on 2010-06-28: Vivus Stock Hinges on FDA Approval of 'Qnexa'; Barron's (VVUS)

Financial news for VVUS dated on 2010-06-24: Volatility On The Move 06-24-2010

Financial news for VVUS dated on 2010-06-24: Shorts In Control 06-24-2010

Financial news for VVUS dated on 2010-06-18: Benzinga's Top Pre-Market Losers (VVUS, ASML, ARMH, QQQQ)

Financial news for VVUS dated on 2010-06-15: Risk Appetite Back 06-15-2010

Financial news for VVUS dated on 2010-06-15: Jefferies Reiterates Hold Rating on Vivus (VVUS)

Financial news for VVUS dated on 2010-06-15: Benzinga's Top Pre-Market Losers (CCNE, VVUS, NFLX, NWSA)

Financial news for VVUS dated on 2010-06-02: Difference Between an ETF & Index 05-28-2010

Financial news for VVUS dated on 2010-06-02: Benzinga's Top Pre-Market Gainers (DIVX, HERO, AMGN, VVUS, JOYG)

Financial news for VVUS dated on 2010-05-28: VIVUS Rising On Heavy Volume Today (VVUS)

Financial news for VVUS dated on 2010-05-25: Benzinga's After Hours Gainers (VRTX, EXC, VVUS)

Financial news for VVUS dated on 2010-05-19: Benzinga's Top Pre-Market Losers (HAUP, GOLD, FSLR, ARMH, VVUS)

Financial news for VVUS dated on 2010-05-18: Benzinga's Top Pre-Market Gainers (SPRD, LLEN, ALTH, FEED, VVUS)

Financial news for VVUS dated on 2010-05-05: Jim Cramer's Mad Money Lightning Round OT Comments (EK, CGA, VVUS, CELG)

Financial news for VVUS dated on 2010-05-04: Benzinga's Volume Movers (NTRI, OSTK, EXBD, IVAC, VVUS)

Financial news for VVUS dated on 2010-05-03: A Look At Bruce Kovner's Portfolio (QCOM, VVUS, FCX, CCL)

Financial news for VVUS dated on 2010-04-27: Brean Initiates Coverage Of Vivus With Buy

Financial news for VVUS dated on 2010-04-14: VIVUS Initiated With Buy

Financial news for VVUS dated on 2010-04-12: Mike Huckman Is Watching VVUS, ARNA, OREX

Financial news for VVUS dated on 2010-03-31: Benzinga's Top Pre-Market Losers (HEAT, LINC, CAGC, VVUS)

Financial news for VVUS dated on 2010-03-26: Delta Neutral Trade in Vivus

Financial news for VVUS dated on 2010-03-26: Benzinga's News Roundup (RSH, FRO, VVUS, BVF)

Financial news for VVUS dated on 2010-03-26: Benzinga's News Roundup (RSH, FRO, VVUS, BVF)

Financial news for VVUS dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for VVUS dated on 2010-03-08: Benzinga's Top Pre-Market Gainers (ITMN, XRTX, SEED, SBLK, VVUS)

Financial news for VVUS dated on 2010-02-04: VIVUS, Inc. (VVUS) Upgraded To Buy

Financial news for VVUS dated on 2010-01-21: Vivus Shares Up 27% Over Three Months

Financial news for VVUS dated on 2010-01-11: Benzinga's Top Pre-Market Gainers (DDSS, IMM, VVUS, LUNA, AA, SOLF, TUES)

Financial news for VVUS dated on 2010-01-11: Benzinga's News Roundup (TAC, BCRX, ASBC, JAH, BP, VVUS)

Financial news for VVUS dated on 2010-01-07: Benzinga's Top Pre-Market Gainers (SPIL, BBBY, SONS, SHLD, TRMD, VVUS)

Financial news for VVUS dated on 2009-12-29: Benzinga's News Roundup (JEF, APPY, VVUS, MS, MSFT, NTRI, UNH)

Financial news for VVUS dated on 2009-12-29: Benzinga's Top Pre- Market Gainers (STEC, VVUS, AIG, VICL, OSIS, AMZN, ASML)

Financial news for VVUS dated on 2009-11-30: Benzinga's Top Pre- Market Gainers (PDLI, NVAX, SIMG, ALTH, SEED, SQNM, VVUS)

Financial news for VVUS dated on 2009-11-19: Vivus (VVUS) Reports Encouraging Results Of Erectile Dysfunction Drug Trials

Financial news for VVUS dated on 2009-11-18: Benzinga's Top Pre- Market Gainers (VVUS, PARD, CSUN, SOLF, NLST, ASMI, CAKE)

Financial news for VVUS dated on 2009-11-05: Jim Cramer Would Stay Away From FUN, POT, VVUS

Financial news for VVUS dated on 2009-11-04: Leerink Swann Lowers Price Target On Vivus To \$9-\$11

Financial news for VVUS dated on 2009-10-30: Pre-Market Movers (CNXT, AXTI, RVSN, VVUS, AIXG)

Financial news for VVUS dated on 2009-10-29: Vivus Results Support Qnexa's Overall Efficacy and Safety Profile, On Track for NDA Filing By End of 2009

Financial news for VVUS dated on 2009-10-26: Vivus Trading Up 15.80% After CEO Appears On CNBC

Financial news for VVUS dated on 2009-09-18: Today's Morning Top Gainers (CBBO,MDM,BPFH,HEAT,VVUS)

Financial news for VVUS dated on 2009-08-13: AnalystChoice.com Brings You the Best Complimentary Research Report on ERIC, CECO, HLIT, VVUS, CPST and ECLP